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ABSTRACT 
Damage to articular cartilage is a particularly perplexing clinical problem because 
cartilage has a limited ability to repair itself. Currently, clinical techniques to treat articular 
cartilage regeneration fail at regenerating fully functional articular cartilage and in extreme cases 
the cartilage regeneration may lead to the need for a total joint replacement. Recently, tissue 
engineering approaches to articular cartilage repair have explored the use of extracellular matrix 
(ECM) based materials for enhanced regeneration of cartilage. ECM-based materials are of 
interest in the tissue engineering field because in all tissues the ECM plays an important role in 
cell function by affecting cell communication, migration, and differentiation. Tissues can be 
decellularized to remove any immunogenic remains of cells to obtain an acellular ECM material 
to be used as a tissue engineering scaffold. The objective of this thesis was to evaluate a 
chemical and physical method for decellularizing articular cartilage and characterizing the 
cellular response to both the un-modified material and the material incorporated into 
microsphere-based scaffolds. Cells cultured in the presence of decellularized cartilage (DCC) 
alone exhibited increased expression of chondrogenic gene markers including collagen II, Sox9, 
and aggrecan relative to negative controls and TGF-β. Additionally, encapsulation of DCC in 
poly(lactic-co-glycolic acid) (PLGA) microspheres had comparable effect on cells in vitro 
compared to the encapsulation of TGF-β. These results indicate that DCC is a promising material 
for future use in cartilage tissue engineering and is worthy of additional future investigation.  
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CHAPTER 1: Introduction 
 
The overall objective of this thesis was to determine the cellular response to cartilage 
matrix in vitro. Cartilage regeneration remains a challenging problem for tissue engineers due to 
the reduced capacity for self-repair. Bioactive biomaterials may have the potential to aid in 
cartilage regeneration by recruiting and inducing differentiation of stem cells. To achieve the 
overall objective, first, porcine cartilage was fully characterized through a combined physical 
and chemical decellularization process. The cellular response to both decellularized cartilage 
(DCC) and devitalized cartilage (DVC) was also assessed in vitro. DCC is cartilage that has been 
fully decellularized via chemical and physical methods. The decellularization process removes a 
majority of the residual DNA and results in an acellular matrix. DVC is cartilage that has been 
devitalized by only physical methods and does not have a direct way of removing nucleic acids 
from the matrix. After fully characterizing the material and cellular response to the un-
manipulated material (i.e., non-crosslinked, non-solubilized), the DCC was incorporated into 
microsphere-based tissue engineering scaffolds by one of two ways: encapsulation in poly(lactic-
co-glycolic acid) (PLGA) microspheres and surface coating of PLGA microsphere-based 
scaffolds.  
Development of a bioactive scaffold containing DCC for articular cartilage regeneration 
followed three specific aims: (1) chemical and physical decellularization of porcine articular 
cartilage, (2) assessing the in vitro BMSC response in the presence of DCC and DVC, and (3) 
incorporating DCC into microsphere-based scaffolds and assessing the response in vitro. 
The first aim characterized cartilage tissue through a chemical and physical tissue 
decellularization protocol. Assessing the loss of DNA after each step during the decellularization 
process assessed the efficacy of the chemical and physical decellularization methods. The 
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biochemical content in the matrix was also measured following each tissue-processing step. The 
second aim used both DCC and DVC to assess the response of BMSCs cultured in pellets in the 
presence of the respective types of cartilage matrices. Cellular response was assessed using RT-
qPCR and DNA content of the cell pellets. Aim 3 investigated the effect DCC had on BMSCs 
when incorporated into microsphere-based scaffolds. DCC was encapsulated in PLGA based 
microspheres and also used to coat the surface of PLGA microsphere-based scaffolds. The 
differences the methods to incorporate DCC (i.e., encapsulation vs. coating) had on cellular 
response were compared to each other as well as to positive and negative controls.  
The organization of the thesis chapters is as follows:  
Chapter 2 contains relevant background information about the bioactivity of cartilage 
matrix materials with respect to cartilage tissue engineering. The chapter outlines the differences 
between the source of cartilage matrices (tissue derived vs. in vitro derived) and the matrix 
processing (decellularization vs. devitalization). Additionally, it discusses the potential 
advantages and disadvantages to using cartilage matrix-based materials in tissue engineering 
applications. Chapter 2 provides insight into the motivation for the following chapters (3 and 4).  
Chapter 3 addresses the first two aims: characterization of cartilage matrix through 
devitalization and decellularization and the cellular response in vitro.  
Chapter 4 focuses on aim 3 involving DCC incorporation into microsphere-based 
scaffolds for cartilage tissue engineering.  
The conclusion of the thesis is chapter 5, which summarizes findings from the two 
experimental chapters. The conclusions from this work are discussed from a global perspective 
with recommendations for future studies.  
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CHAPTER 2: The Bioactivity of Cartilage Extracellular Matrix in Articular 
Cartilage Regeneration 
 
ABSTRACT 
Cartilage matrix is a particularly promising acellular material for cartilage regeneration 
given the evidence supporting its chondroinductive character.  The ‘raw materials’ of cartilage 
matrix can serve as building blocks and signals for enhanced tissue regeneration. These matrices 
can be created by chemical or physical methods: physical methods disrupt cellular membranes 
and nuclei but may not fully remove all cell components and DNA, whereas chemical methods 
when combined with physical methods are particularly effective in fully decellularizing such 
materials. Critical endpoints include no detectable residual DNA or immunogenic antigens. It is 
important to first delineate between the sources of the cartilage matrix, i.e., derived from matrix 
produced by cells in vitro or from native tissue, and then to further characterize the cartilage 
matrix based on the processing method, i.e., decellularization or devitalization. With these 
distinctions, four types of cartilage matrices exist: decellularized native cartilage (DCC), 
devitalized native cartilage (DVC), decellularized cell derived matrix (DCCM), and devitalized 
cell derived matrix (DVCM). Delivery of cartilage matrix may be a straightforward approach 
without the need for additional cells or growth factors. Without additional biological additives, 
cartilage matrix may be attractive from a regulatory and commercialization standpoint. Source 
and delivery method are important considerations for clinical translation. Only one currently 
marketed cartilage matrix medical device is decellularized, although trends in filed patents 
suggest additional decellularized products may be available in the future. To choose the most 
relevant source and processing for cartilage matrix, qualifying testing needs to include targeting 
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the desired application, optimizing delivery of the material, identify relevant FDA regulations, 
assess availability of raw materials, and immunogenic properties of the product.   
 
INTRODUCTION 
Articular cartilage injuries present a unique and challenging medical problem due to the 
tissue’s lack of regenerative ability. The reduced vascularity, limited cell population, and dense 
extracellular matrix (ECM) inhibit cartilage regeneration. Untreated cartilage defects due to 
osteoarthritis or injury can lead to swelling, joint pain, and further degeneration of the tissue and 
eventually the need for a total joint replacement.1  
The goal of cartilage regeneration and repair is to produce fully integrated tissue at both 
the articular surface and the subchondral bone that has mechanical and chemical properties 
similar to native cartilage.2 Many current surgical cartilage defect treatments such as autologous 
chondrocyte implantation (ACI), microfracture, osteochondral transplantation (mosaicplasty), 
and current allograft implants usually do not produce fully integrated tissues, tissues with native 
mechanical strength, or tissues with the same composition as native articular cartilage.1, 3, 4 
Freezing allograft implants can decrease the cellularity of the grafts and can in turn cause the 
implant to have inferior clinical outcomes compared to fresh allograft tissues.5 These treatment 
options may also be associated with additional surgical risks and time to regain joint function.  
The tissue engineering field has recently seen an emerging trend toward acellular 
biomaterials as an alternative to cell-based therapies.4, 6 In particular, the ECM in a variety of 
tissue types can be used as an acellular biomaterial through decellularization or devitalization 
processes. It is important to distinguish between the sources of the cartilage matrix (in vitro vs. 
tissue derived) and to further characterize cartilage matrix by either decellularization or 
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devitalization processing (Fig. 2.1). Decellularized native cartilage (DCC) can be obtained from 
human cadavers or xenogeneic sources and is typically decellularized via chemical processes, 
usually combined with physical methods to remove nearly all cells and residual cellular 
components. Native devitalized cartilage (DVC) can also be obtained from human or xenogeneic 
sources, but is subjected to only physical processing such as freeze-thaw cycles or freezer-
milling without any chemical decellularization agents. Physical methods disrupt cellular 
membranes and nuclei but may not fully remove cellular DNA, cell associated proteins, and 
other cell remnants (e.g., phospholipids). Decellularized cell-derived matrices (DCCM), in 
contrast, are ECM materials secreted by cells in vitro that have been chemically decellularized.  
Devitalized cell-derived matrices (DVCM) are cell-derived matrices that have been devitalized 
via physical methods only. Cell derived matrices are generally less dense than native tissues and 
may not contain the same composition as native tissues. 
Acellular tissues are promising biomaterials because they contain the materials found in 
native ECM, which can provide a unique microenvironment for cells that is dependent upon the 
tissue. These materials may provide both chemical and mechanical signals to aid in 
differentiation of stem cells and the regeneration of the tissue.6 ECM materials can also be 
constructively remodeled and act as building blocks for the newly formed tissue instead of being 
degraded and removed. Many tissue types have been successfully decellularized including small 
intestinal submucosa (SIS), muscle, liver, kidney, adipose, tendon, colon, and heart valves.7-11 
Other tissues that have been decellularized have varying results with respect to their mechanical 
properties, biochemical content, and structure following decellularization.  In general, less dense 
tissues are able to be decellularized more efficiently and can maintain their microstructure 
following decellularization. In all tissues, increasing exposure time to decellularization agents 
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decreases the mechanical integrity and structure of the tissue. Decellularized heart valves have 
been implanted in patients with little early success; however, SIS matrix has been successful in 
repair of numerous tissues.12-14  
 Hyaline cartilage is an ECM-rich tissue with approximately 95% of the dry weight being 
made up of ECM.15 The primary components of hyaline cartilage ECM consist of the 
proteoglycan aggrecan, which itself is rich in glycosaminoglycans (GAGs), and collagen II. 
Because of the rich ECM nature of cartilage, decellularization of the material may result in high 
material yields of the native ECM components. The high density of articular cartilage, however, 
presents a challenge to effective decellularization.  
 The field of tissue decellularization is well developed in the cardiovascular field, but has 
only recently begun developing in the hyaline cartilage field. According to the Web of Science 
citation report on March 21, 2014, the decellularized cartilage topic has seen a marked increase 
in publications in the past decade, with over 20 publications reported in 2013 compared to only 
one in 2003. Previous reviews of acellular biomaterials and the use of ECM for osteochondral 
tissue engineering have covered these topics extensively with a broad overview.1, 4 While these 
reviews have successfully introduced the field of acellular ECM materials for cartilage and bone 
tissue engineering, they have not clearly defined and delineated the differences between cartilage 
matrix sources or processing techniques, nor have implications of putative pathways for Food 
and Drug Administration (FDA) approval and commercialization been considered. Prior studies 
in the cartilage matrix field lack cohesiveness that follow similar methods to evaluate cartilage 
matrix materials including acellular controls to evaluate biochemical and DNA content of 
scaffolds and pre-implantation mechanical testing. This current review addresses the differences 
between decellularization and devitalization of native tissues and cell derived matrices, current 
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decellularization and devitalization methods used for cartilage matrices, the ways in which 
cartilage matrix has been incorporated into tissue engineering scaffolds, the immunogenicity of 
decellularized and devitalized tissues, and the future of cartilage matrix as a translational 
biomaterial for cartilage regeneration. 
 
NATIVE CARTILAGE MATRIX 
 
Native cartilage matrix is cartilage derived from articulating joints of either human or 
animal sources.  The composition of native cartilage may vary depending on the donor 
organism’s species, age, health status, and other genetic factors.16-18 Certain disease states, 
particularly osteoarthritis, will produce articular cartilage with reduced amounts of GAG and 
collagen II.18 Zonal variations (i.e., the depth at which it is collected) within the articular 
cartilage structure are also an important factor to consider with respect to the composition of the 
harvested material. 
 
Decellularized Native Cartilage Matrix (DCC) 
Chemical decellularization of cartilage is a method that primarily uses chemicals to lyse 
and remove the cells and their components from the surrounding ECM. Frequently used 
detergent decellularization chemicals include sodium dodecyl sulfate (SDS) or sodium lauryl 
sulfate (SLS), EDTA, Triton X-100, and Tris-HCl (Table 1).19-22 Various formulations of 
DNases and RNases are also commonly used to remove nucleic acids from the material.22, 23 
Many chemical decellularization protocols encompass some combination of these chemicals. 
Because of the dense nature of articular cartilage, to improve the efficiency of chemical 
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decellularization the native macro-structure must often be disrupted, which allows the material to 
be more effectively exposed to the chemical decellularization agents for shorter amounts of 
time.15 This may include mincing the cartilage into small particles or freezer-milling prior to the 
chemical decellularization process. Successful decellularization of intact cartilage slices has 
occurred, however, little GAG was retained within the matrix and the resulting material was 
primarily collagen.24 The shorter exposure times to decellularizing agents that can be achieved 
by first mechanically processing the tissue is often beneficial for the retention of the 
microstructure including GAG and collagen II concentration while more effectively decreasing 
in double stranded DNA content. However, by sacrificing the macrostructure of the matrix, the 
mechanical integrity of the tissue is also compromised.25  
The use of chemical detergents to decellularize cartilage results in a significant decrease 
in the amount of whole cells, cell nuclei, and DNA present in the tissue. Hematoxylin and eosin 
staining (H&E), immunohistochemistry (IHC), SEM imaging, mass spectrometry, ELISA, and 
quantitative DNA assays have confirmed the reduction of cells, cell fragments, cell associated 
proteins, and nucleic acids in chemically decellularized cartilage.19, 21, 22, 24, 26, 27 Chemical 
decellularization methods such as 2% SDS treatment for 2 hours or tritonX-100, EDTA and 
nuclease treatment have also shown that the DCC can retain collagen II and GAGs in the 
material and has been confirmed by immunofluorescent staining, histological staining, 1,-9,-
Dimethylmethylene Blue (DMMB) sulfated GAG assay, and chloramine-T hydroxyproline 
assay.23, 28 The amount of GAG retained in DCC, however, significantly decreased with 
increasing chemical decellularization, while collagen II levels did not significantly decrease.28 A 
reduction in GAG content may be undesirable based on previous studies that have shown that 
certain GAGs such as aggrecan are chondroinductive.29, 30 Biomechanical properties such as the 
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aggregate modulus and linear modulus have also decreased following decellularization agent 
exposure.24, 28, 31 The decellularization chemicals used in studies with decreased mechanical 
performance included: 2% SDS treatment, a non-enzymatic treatment with NaOH, ethanol, 
guanidine HCl-sodium acetate solution, H2O2, and NaCl, and another non-enzymatic method 
with washes of NaOH and H2O2. Although stiffness may be diminished following 
decellularization, Schwarz et al.31 reported DCC regained as much as 77% of native cartilage 
stiffness after 42 days of in vitro culture with human chondrocytes after decellularization with 
NaOH, ethanol, guanidine HCl-sodium acetate solution, H2O2, and NaCl. 
In vitro culture of canine bone marrow-derived mesenchymal stem cells (BMSCs) on a 
canine derived DCC scaffold have also differentiated into chondrocyte-like cells when cultured 
in chondrogenic differentiation media.20 The BMSCs attached to the scaffold and exhibited a 
round or elliptical morphology confirmed by SEM.20 Chondrogenically-induced canine MSCs 
also attached and proliferated on human derived DCC scaffolds after 21 days of culture 
confirmed by PKH26 imaging, SEM, IHC, and histology.22  
In vivo implantation of DCC has been shown to enhance defect repair with implanted 
with pre-differentiated rabbit ASCs confirmed by histology, IHC, and biochemical quantification 
of GAG and collagen II content after 6 months implanted in rabbits (Table 2).32 These scaffolds 
seeded with exogenous cells produced regenerated tissue with 83% of native cartilage stiffness 
after 6 months.32 ASCs also attached to the DCC scaffold and exhibited a round morphology 
confirmed by SEM when seeded on DCC scaffolds.32, 33 Other in vivo implantations of DCC 
scaffolds in canine knee osteochondral defects seeded with canine BMSCs showed that after 3 
and 6 months, the defects were filled with higher quality and better integrated tissue than control 
groups implanted with scaffolds and without predifferentiated BMSCs.20 At 6 months, the repair 
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cartilage exhibited 70% stiffness of native cartilage.20 Comparisons by gross morphology, 
histological examination, and micro-CT analysis between experimental and control groups were 
all in agreement. Using a similar biphasic scaffold for femoral head osteochondral defects, 
however, resulted in failure of the implant leading to collapse of the femoral head and severe 
osteoarthritis.34 Proposed mechanisms of failure included accelerated degradation of the 
cancellous bone region of the scaffold, ischemic conditions, and high load bearing conditions.34 
Implantation of DCC scaffolds seeded with ASCs also produced superior defect healing 
compared to groups without cells or no scaffold as confirmed by histological observation.32  
If DCC is desired for a tissue engineering application, the best route of delivery to the 
defect site must be determined.  DCC used in tissue engineering can be incorporated or made 
into some type of scaffold that has both form and mechanical function, but when used in joints, 
the scaffold must support relevant compressive and shear loads. A common scaffolding 
technique used with DCC following chemical decellularization is freeze-drying followed by 
crosslinking. The crosslinking may be achieved by various methods including genipin, 
ultraviolet radiation, carbodiimide chemistry, and dehydrothermal treatment.20, 32, 33  
A sandwich model for tissue engineering DCC scaffolds has been reported that consists 
of layers of DCC sheets and chondrocytes.19 This particular sandwich model used thin sections 
of porcine ear cartilage (10 or 30 µm) obtained through freeze sectioning of the tissue. The 
decellularization was carried out via 1% SDS after the freeze sectioning and the DCC sheets 
were then stacked alternatively with chondrocytes. This scaffold technique can be used to create 
different shapes and sizes of scaffolds.  
DCC has also been combined with synthetic biomaterials such as poly(lactide-co-
glycolide) (PLGA) to create scaffolds: porcine DCC was added to PLGA (70/30) dissolved in 
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dioxane at a concentration of 7% (w/w) and after using a temperature based phase separation, the 
scaffold was freeze-dried in a mold.35 The DCC particles that were used were fibrous and aligned 
vertically in the scaffolds by a temperature guided phase separation. SEM confirmed the 
orientation of DCC fibers and uniform, interconnected pores in the scaffold.   
Native articular DCC has also been digested by pepsin to create an injectable hydrogel 
for drug delivery purposes.36 The DCC hydrogel was found to sustain release of a fluorescently 
labeled protein for up to 22 days in vivo in rats. This hydrogel could potentially also be used for 
tissue engineering applications that include release of bioactive proteins to aid in regeneration or 
disease mitigation.  
In summary, chemical decellularization of cartilage tissue is an effective method for 
removing cells and their components from the surrounding ECM. This type of decellularization, 
however, may alter the biochemical composition of the ECM, including a reduction of GAG 
content. Chemical decellularization also may require complete destruction of the tissue 
macrostructure rendering the resulting material mechanically unstable. For delivery to defect 
sites, DCC that has been chemically and physically processed may require additional 
manipulation to fabricate mechanically functional scaffolds. In vitro and in vivo studies have 
shown favorable responses such as chondrogenic differentiation of stem cells and improved 
defect repair with chemically decellularized cartilage.   
 
Devitalized Native Cartilage (DVC) 
 
Physical devitalization of tissue uses physical methods to disrupt cellular functions or 
lyse cells within a tissue. One example is freezer-milling followed by heat-inactivation to 
inactivate the cells found in the tissue without removing cells and all cellular components.37 
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Freezer-milling pulverizes the tissue into particles at low temperatures and the tissue is then heat-
inactivated in a gravity oven. Devitalization can also be accomplished through hydrated tissue 
homogenization followed by retrieval of tissue particles, freezing, and lyophilization.38, 39 Freeze 
thaw cycles followed by sonication has also been used to devitalize CDM constructs and could 
conceivably be used to devitalize native cartilage.40 
Physical devitalization of articular cartilage does not have direct means to remove 
cellular components after deactivation of the tissue. The effect of physical devitalization on the 
ECM composition has not been widely reported in tissue engineering applications. Yang et al.39 
found following devitalization via tissue homogenization and centrifugation that GAG and 
collagen II remained in the DVC matrix confirmed by histology and IHC. Most studies reporting 
the use of physical devitalization to process DVC have not confirmed loss of DNA or retention 
of GAG or collagen content. Studies exploring the freezing and thawing of tissues for 
cryopreservation have shown that freezing cartilage induces apoptosis and necrosis in 
chondrocytes.41 Freezing the tissue causes extracellular ice crystals to form that may cause an 
osmotic imbalance within the tissue creating acidic conditions, which activate degradation 
enzymes that degrade collagen fibers. This degradation of ECM components, however, may be 
minimal, as Szarko et al.42 found no detectable change in collagen and GAG content following 
one freeze-thaw cycle. The rate of freezing and thawing can be controlled to attempt to preserve 
the ECM. One study has suggested that fast thawing conditions can help maintain the mechanical 
integrity of the tissue and that the temperature at which the tissue is frozen does not affect the 
cartilage stiffness.42 Protease inhibitors may also be used to increase the preservation of the ECM 
during freeze-thaw cycles.43 For a complete review of cryopreservation induced stresses in 
articular cartilage, the reader is directed to Kaur et al.41  
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Comparing human devitalized cartilage particles via heat inactivation and native cartilage 
particles shows that heat-inactivated cartilage particles exhibited a reduced formation of 
neocartilage compared to cartilage particles that were not devitalized when implanted in a 
critical-sized chondral defect in immunocompromised rats for 28 days.37 Cartilage particles 
alone, heat inactivated or not, did not induce high quality chondrogenesis without the addition of 
exogenous growth factors. Peretti et al.44 reported that when comparing porcine live and 
devitalized cartilage implants’ formation of neocartilage when implanted subcutaneously in nude 
mice, porcine chondrocytes suspended in fibrin glue sandwiched between devitalized constructs 
saw a delay in neocartilage formation over an 8 week period. Analysis was performed using 
confocal microscopy and histological staining and compared to acellular fibrin glue and cartilage 
controls. The acellular control groups without cells in the fibrin glue did not produce cartilage-
like matrix. This suggests that although devitalized cartilage may have a delayed effect compared 
to live cartilage on neocartilage formation, neocartilage formation could still be possible with the 
use of devitalized cartilage when seeded with exogenous cells.44   
Cartilage that had been devitalized by homogenization of the tissue was molded into 
scaffolds and seeded with ASCs. The constructs were cultured in chondrogenic differentiation 
medium without exogenous growth factors and showed significant up regulation aggrecan and 
collagen II gene expression after 14 days.38 Biochemical analysis also revealed statistically 
significant decreasing GAG content after 42 days.  
DVC has been incorporated into electrospun scaffolds by combining solubilized DVC 
with poly(ε-caprolactone) (PCL). The mixture was electrospun into single and multiple layer 
porous constructs.45 When seeded with P4 human ASCs the DVC-PCL constructs showed 
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increased GAG and dsDNA content at times 0, 14, and 28 compared to PCL only constructs in 
vitro.   
In vitro studies with DVC followed similar trends as DCC with respect to mechanical 
performance. Cheng et al.38 reported that the aggregate modulus of frozen and lyophilized DVC 
increased over 28 days when cultured with human ASCs in incomplete chondrogenic 
differentiation medium. DVC has also been incorporated into scaffolds with synthetic polymer 
components such as PCL. Woven PCL-DVC constructs had a lower aggregate modulus than 
PCL constructs alone but a greater aggregate modulus than DVC constructs alone.46 The 
aggregate modulus of DVC scaffolds can also be increased by increasing the crosslinking 
percentage as reported by Cheng et al.33 
In summary, physical devitalization of cartilage deactivates the tissue without removing 
the cells and their components; however, the effect on the tissue’s ECM is unknown when 
devitalizing native articular cartilage. When cultured in the presence of devitalized cartilage, 
ASCs have undergone chondrogenic differentiation.38 Devitalized cartilage has been shown to 
have the ability to induce neocartilage formation when implanted subcutaneously.44  
 
CELL DERIVED MATRIX (CDM) 
CDM is derived from cells grown in vitro, whether in monolayer or 3D culture. CDM can 
be obtained from mesenchymal stem cells (MSCs), fibroblasts, chondrocytes, preosteoblasts, or 
any other cell type that can be induced to excrete cartilage-like matrix.47, 48 Different cell types 
can be mixed or the resulting ECM materials can be combined to create mixed or gradient tissue 
scaffolds. CDM cannot be obtained until the cells have been cultured long enough to secrete 
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ECM materials, which can require up to 3 weeks.49 Perfusion bioreactors have been used to 
encourage cell deposition of ECM in vitro and may be used for increased ECM production.50, 51  
The effect that the CDM has on tissue regeneration and cellular response has been shown 
to be dependent on the age of the cells secreting the matrix. CDM from fetal human synovium-
derived stem cells (SDSCs) had greater positive effects on stem cell proliferation, differentiation, 
and mechanical functionality compared to CDM from adult SDSCs.52  
Cells can be seeded into 3D scaffolding materials such as open-cell foams to create CDM 
constructs with tunable 3D geometry and composition, after which the synthetic foam can be 
removed.53 This process creates a porous ECM-derived scaffold that may then be decellularized 
without additional manipulation of the matrix such as crosslinking. The synthetic portion of the 
3D constructs may alternatively remain as part of the tissue engineering scaffold with the CDM 
that has been deposited onto the surface of the synthetic material.40, 50  
A benefit of CDM is that it may be created from an autologous or allogeneic source to 
reduce the possibility of a negative immunological response. If autologous CDM is attainable, 
decellularization or devitalization may not be necessary but the product would need to be 
specially produced for each patient and therefore there would be no off the shelf product. The 
procedure to create autologous CDM must overcome many of the same challenges associated 
with the current ACI treatment including the need for two surgeries, the time between surgeries 
required to wait for the cells to expand in vitro, good manufacturing practice (GMP) facilities to 
culture the cells and associated costs, and thus also health insurance reimbursement. Another 
challenge with CDM is that the cells must remain in the differentiated state to excrete the correct 
type of ECM material. CDM is also obtained in smaller quantities in a greater amount of time 
than native cartilage tissue. To observe enhanced chondrogenesis, in vitro exogenous growth 
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factors may be necessary.51, 54 The composition of CDM may also vary from that found in typical 
native tissue, and reproducibility may also become a concern.  
 
 
Decellularized Cell-Derived Cartilage Matrix (DCCM) 
DCCM is CDM that has been fully decellularized. Because CDM is less dense than 
native cartilage, the decellularization process is generally shorter, less abrasive to the matrix 
materials, and more efficient at cell removal.1, 40 Mechanical methods that are usually paired with 
chemical decellularization for efficient decellularization of DCC are usually not necessary. 
DCCM was shown to be susceptible to decreasing aggregate modulus with long decellularization 
protocols.25 The type of chemical used to decellularize DCCM also affects the aggregate 
modulus. A greater aggregate modulus can be maintained for chondrocyte derived DCCM with 
1% SDS, 2% SDS, and 2% TnPB treatments for 1 hour.25 Increasing exposure to these methods 
for 8 hours significantly reduces the aggregate modulus. Decellularization treatments of 2% 
Triton-X or osmotic shock both significantly decrease the aggregate modulus of DCCM 
constructs after 1 hour of exposure.25  
    
Devitalized Cell-Derived Matrix (DVCM) 
DVCM is derived from cells in vitro just as DCCM. However, DVCM is devitalized via 
physical processes instead of chemical methods. As with DVC, there is no means to fully remove 
the DNA from the matrix. When using cell derived matrix, however, Levorson et al.40 has shown 
a large decrease in DNA, GAG, and collagen content following freeze thaw cycles and 
sonification of DVCM constructs. This may be due to the large differences between native and 
cell derived matrices in their density and composition. DVCM has the same benefits as DCCM 
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such as the easy manipulation of the matrix orientation and the ability to coat synthetic surfaces. 
The physical methods to devitalize the construct must be considered if the material is also 
combined with synthetic materials as the methods may alter the synthetic material composition 
or mechanical properties.  
In summary, CDM is derived from in vitro cell culture and can be easily decellularized 
and devitalized largely due to the low density of the matrices. DCCM and DVCM can be created 
from many different cell types and can further be incorporated into tissue engineering scaffolds 
by either coating synthetic materials or crosslinking constructs.  
 
CLINICAL TRANSLATION 
 
Decellularized materials are attractive options from a commercialization and regulatory 
approval standpoint. Because the tissue can be processed in a way that removes cellular 
components and ECM antigens, the decellularized tissues may be negligibly immunogenic and 
conducive to FDA approval. Operational costs of maintaining viable tissue could also be 
decreased because the decellularized tissue may be stored for longer periods of time before use 
than cellular allografts.  
Only one currently marketed cartilage repair technique employs the use of cartilage 
matrix that has been decellularized. Zimmer markets a product called the Chondrofix® 
Osteochondral Allograft, which is a decellularized allograft plug designed for osteochondral 
regeneration therapy.55 The osteochondral device is treated to remove potentially harmful viruses 
and lipids and to sterilize the tissue and contains distinct cartilage and bone regions.  There are 
no available clinical results describing the efficacy of the decellularized allograft.  
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Zimmer also markets the DeNovoTM NT Natural Tissue Graft, which is particulated 
juvenile human cartilage allograft for osteochondral defect repair.56 The juvenile cartilage 
allograft has a greater chondrocyte density and greater regenerative potential and has been shown 
to create hyaline-like cartilage in vivo in goats.57 The resulting neocartilage from juvenile human 
chondrocytes did not elicit a T-cell-mediated immune response in goats.57 This treatment option 
is primarily a cell-based approach as it relies on the potential of the juvenile chondrocytes. This 
product is only available for special orders and is not readily available off the shelf.  
Arthrex markets BioCartilage®, a one step treatment that contains a combination of 
micronized human cartilage particles and autologous platelet rich plasma (PRP) to be used with 
microfracture techniques.58 In a study with baboons, BioCartilage® was shown to promote 
chondral lesion regeneration without any adverse immunological reactions.58  
 Although the medical device field has only one decellularized tissue option for chondral 
or osteochondral regeneration, numerous patents describe cartilage decellularization and 
scaffolding techniques (Table 3).55, 56, 59-68 These patents may indicate an increasing trend in 
products that have been decellularized to treat chondral and osteochondral defects. The FDA first 
approved a decellularized xenograft surgical mesh in 1998. A decellularized heart valve allograft 
and a decellularized pulmonary artery patch were also approved in 2008 via the 510(k) route. 
Shortly after, the Zimmer Chondrofix® implant was put on the market in 2011. The Chondrofix 
decellularized allograft is classified by the FDA as a human cell or tissue product (HCT/P) and 
therefore does not require investigational new drug or device exemption approval. With this 
precedent, this route may be likely for subsequent decellularized cartilage options as long as 
there is no additional cellular component or engineering to attract enhanced homing of stem cells 
in vivo. The material would likely need to be fully decellularized and, if xenogeneic, free of all 
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antigens. Lastly, the device would benefit from comparable mechanical properties to currently 
used allograft implants.   
 To summarize, there is only one truly decellularized cartilage matrix product currently on 
the market, however, without available clinical results the efficacy of the implant cannot be 
assessed. Patents suggest that decellularized cartilage matrix products may become increasingly 
available in the future. Limitations to currently marketed strategies such as reliance on cell 
viability and special orders further highlights the potential desirability of acellular cartilage 
matrices for therapeutic treatments as the viability of cells does not need to be considered and the 
final products may be available as off the shelf products. 
 
IMMUNOGENICITY OF CARTILAGE MATRIX 
Host immune response to tissue grafts can arise from cell surface markers, ECM 
epitopes, and residual DNA. Little work has been done to determine the immunogenicity of 
chondral and osteochondral xenograft implants. Cartilage-only repair treatments are somewhat 
immuno-privileged as compared to osteochondral approaches that expose the scaffold construct 
to the subchondral bone. The majority of research to determine the immune response due to 
decellularized xenograft implants has been assessed in cardiovascular implants, however, these 
findings may be valuable for osteochondral and cartilage only decellularized implants.69-71 
 
Residual DNA Response   
 
Studies have assessed the effect of differing decellularization levels of porcine small 
intestinal ECM (SIS) on macrophage phenotypes in vitro and in vivo.72 Macrophages are 
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important for immune defense and normal tissue remodeling. Generally, for tissue engineering, 
M2 macrophage populations mark a repair and remodeling response whereas M1 macrophages 
represent a destruction and elimination response. Keane et al.72 found that the more aggressive 
decellularization technique that resulted in the greatest reduction in DNA with only a small 
amount of short fragments remaining in the tissue helped to promote the macrophage phenotype 
to M2 in vitro.72 However, in some cases a construct with greater amount of DNA in the tissue 
had a smaller M2 population than tissue with slightly less residual DNA. These opposing results 
may suggest that residual DNA within the tissue is not the only determinant of host 
immunological response.  
Another study exploring the role of residual DNA in the immunogenicity of 
decellularized heart valves found that even with complete cell removal that human monocytic 
cells were attracted to the matrix in vitro.73 This study also found that residual DNA was not the 
only factor in eliciting an adverse immunological response and that antigenic epitopes found in 
xenogeneic tissues may also play a role.  
 
Alpha-Gal Epitope Response  
 
Other causes of immunological responses may be due to the disaccharide galactose 
(α1,3)galactose (alpha-Gal epitope) found commonly in xenogeneic tissues.74 The alpha-Gal 
epitope is commonly found in xenograft materials originating from nonprimate animals and is a 
carbohydrate found within the ECM.75 The removal of alpha-Gal is important because it does not 
follow previous assumptions that the immunogenicity of xenograft materials arises solely from 
residual cells. One case in which the alpha-Gal epitope was not been fully removed was reported 
with a decellularized heart valve, Synergraft.76 Due to both the presence of the alpha-Gal 
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epitope, incomplete decellularization, and inferior mechanical properties, clinical implantation of 
these decellularized grafts failed early when implanted in pediatric patients.12 Methods to reduce 
the antigenicity of xenogeneic materials have been studied including the solubilization of 
proteins to enhance antigen removal from decellularized bovine pericardium.77 In the bovine 
pericardium example, the solubilization of proteins during the decellularization process enhanced 
the removal of xenogeneic antigens and exhibited reduced antigen levels compared to 
decellularization protocols alone.  
Some currently employed decellularization protocols, however, have reported effectively 
removing the alpha-Gal epitope during the decellularization process without additional 
enzymatic treatment such as alpha-galactosidase in bovine ligament and sheep artery tissues.71, 75 
The sheep tissue was tested for immune responses as an allograft material in vivo. Bovine tissue 
was tested in vitro using human peripheral blood mononuclear cells (PBMCs). Both of these 
studies found that the removal of the antigens in the decellularized tissue resulted in reduced 
immunogenicity of the tissue.  
Physically devitalized human cartilage fragments (DVC) have been evaluated for host 
immune responses in immunocompromised rats.37 Histological examination showed that there 
was no significant inflammation in the rats. In a separate study, porcine DCC was created from 
both physical processing and chemical decellularization and was devoid of the alpha-Gal epitope 
following decellularization as confirmed by immunohistochemistry.26 The staining of fresh 
cartilage showed there was no expression of the alpha-Gal epitope in the tissue and the epitope 
was primarily found in the subchondral bone region. The decellularized porcine tissue was 
implanted subcutaneously in GTKO mice and showed a reduced fibrous capsule thickness and 
greater cell infiltration.26 Although antigen removal from decellularized tissue may negatively 
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impact the material’s mechanical performance or biochemical content, the removal of the antigen 
is important for successful xenotransplantation.24 
 
Human Leukocyte Antigen (HLA) Response  
HLA genes encode for cell surface antigens expressed by host cells. Normal HLA 
function is essential for disease defense and recognizing “non-self” antigens. Decellularization of 
human heart valves has shown that decellularized grafts elicited reduced anti-HLA antibody 
formation than implants that were not decellularized.70 Fresh allografts are particularly difficult 
to reduce HLA antigenicity because the HLA antigens remain in the matrix. Since osteochondral 
allografts are composites of two tissue types, the immunological response may be varied. It has 
been hypothesized that much of the immune response to osteochondral allografts are due to the 
bone region of the implant.78, 79 The dense nature of articular cartilage may help reduce immune 
response to the cartilage region because the cells are deeply embedded within the matrix and not 
easily assessable to immune cells. By matching HLA antibodies between host and donor tissues, 
the success and integration of allografts has been increased.79 Hunt et al.79 showed that increased 
HLA antibody formation was correlated with a greater diameter of the implanted osteochondral 
graft.   
It has been shown that residual DNA is not the only cause of an unfavorable immune 
response. Although the most exhaustive immunological testing of decellularized tissues has been 
performed on cardiovascular implants, efforts have been made to ensure complete removal of the 
alpha-Gal epitope and HLA antigens from decellularized cartilage matrices. The removal of 
xenogeneic and cell surface antigens is important for successful implantation of xenogeneic or 
allogeneic material to ensure cell infiltration into the implanted material and successful repair of 
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the tissue, however, if using human tissue, alpha-Gal antigen removal is not needed, but careful 
attention to HLA type may be necessary.  
 
RECELLULARIZATION AND HOST INTEGRATION 
 
Recellularization of decellularized or devitalized cartilage matrices that have not been 
mechanically processed may be difficult because of the dense ECM. A proposed solution to the 
difficulty of repopulating cartilage ECM is to use microscopic units of cartilage matrix.15 For an 
in depth review of the rationale for using microscopic donor units, the reader is directed to 
Ghanavi et al.15 Using microscopic cartilage matrix units greatly decreases the distances required 
to travel by cells and allows greater infiltration into the tissue. Cartilage matrix materials that 
have been mechanically disrupted into small particles have then been crosslinked or freeze-dried 
to create scaffolds with large macroscopic pores that have shown to have successful cell 
infiltration and attachment in the scaffold.20, 38 Another method that has been used to encourage 
cell infiltration into the dense cartilage matrix is to use thin sections of cartilage matrix (10 or 30 
m) as used by Gong et al.19 The constructs with 10 m thick cartilage matrix had a greater 
amount of penetrating lacuna that allowed for successful cell infiltration into the matrix. CDM 
coatings on synthetic biomaterial scaffolds also allow for constructs with greater porosity such as 
CDM coating on PCL electrospun scaffolds or other polymer-based scaffolds.51, 80 CDM 
constructs fabricated using open-cell foams also result in scaffolds with high porosity to allow 
for cell migration and infiltration.53 Decellularization of intact cartilage (no mechanical 
processing) may benefit from a significant decrease in GAG content to increase the porosity of 
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the matrix.24 While this decrease in GAG content may aid in successful recellularization, the 
mechanical properties are greatly decreased with an approximately 70% reduction in stiffness. 
 Graft incorporation into host tissue is vital to successful long-term implantation of 
cartilage matrices for cartilage defect repair. The dense nature of articular cartilage makes host 
cell infiltration within the cartilage difficult and limited. However, it has been suggested that 
when implanting fresh osteochondral allografts with viable donor cells, host infiltration is not 
desired as host remodeling will promote formation of fibrocartilage and destroy the intact 
articular cartilage.78 Studies exploring the use of DCC for cartilage regeneration have seen 
successful host integration when exogenous cells were added prior to implantation (Table 1.2). 
When compared to acellular scaffold controls, groups containing exogenous cells generally 
showed greater repair and regeneration including at the defect boundaries.   
 In summary, cartilage matrices have recently been manipulated to make the products 
more clinically relevant by creating scaffolds with larger pore sizes than found in native 
cartilage. This allows for greater cell infiltration and migration within the scaffolds. In vivo 
studies have reported successful integration of cartilage matrix based scaffolds in both 
osteochondral and cartilage only defects.  
 
CHONDROINDUCTIVE NATURE OF CARTILAGE MATRIX 
Cartilage matrix has been shown to have chondroinductive effects on cells in vitro. Human ASCs 
have differentiated into chondrocyte-like cells when cultured in vitro in the presence of porcine 
DCC.33, 38 Both aggrecan and collagen II gene expression were increased over a 2-3 week period. 
Porcine DCC has also been shown to influence P1 human chondrocyte gene expression by 
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increasing both collagen II and aggrecan expression levels in vitro.31 GAG production in vitro 
was also shown to increase when human chondrocytes were cultured in the presence of porcine 
DCC. Upregulation of aggrecan and collagen II gene expression has also been reported in 
dedifferentiated rat chondrocytes when cultured on fibroblast-, preosteoblast-, and chondrocyte-
CDM.47 
 Human and porcine chondrocytes seeded on DVC constructs were both shown to 
proliferate and secrete GAG based on PicoGreen and DMMB assays without any added growth 
factors.81 Histology and IHC showed the presence of collagen II and GAG in both human and 
porcine cell seeded constructs.  In a separate study, human MSCs seeded on DVC constructs 
subjected to different crosslinking methods (UV, carbodiimide, and dehydrothermal) reported 
that crosslinking of DVC may help chondrogenesis.54 Increases in DNA, GAG, and collagen 
content were reported in crosslinked groups compared to a noncrosslinked control without 
additional growth factors.  
 When solubilized DVC was incorporated into poly(ε-caprolactone) (PCL) electrospun 
scaffolds, chondrogenic differentiation of human P4 ASCs was also seen when compared to 
control PCL only constructs. Aggrecan gene expression was increased after 7 days in vitro.45 
Both collagen content and GAG content significantly increased between control PCL constructs 
and DVC-PCL constructs at 0, 14, and 28 days.  
 Little is currently known about the mechanism by which cartilage matrix promotes 
chondrogenesis. Proposed hypotheses include: ECM influence on cell shape, ECM stiffness, 
residual bound growth factors, ECM structure, or ECM biochemical content (GAG and 
collagen).47, 81, 82 The decellularization or devitalization protocol used may affect either the 
biochemical content or the residual growth factors within the matrix. Wong et al.77 demonstrated 
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that by altering existing decellularization protocols to keep proteins solubilized, they were able to 
effectively remove protein antigens from the tissue. Altering decellularization conditions to 
remove small antigenic proteins may also remove growth factors. Devitalization techniques such 
as freeze-thaw cycles may also increase the degradation or denaturation of latent growth factors 
within the ECM by activating degradation enzymes or pH changes due to physiochemical 
chemical stress within the tissue.41 Additional studies are needed to determine the mechanism of 
chondrogenesis seen in cartilage matrix-based scaffolds. 
 The ability of cartilage matrix to influence the differentiation or re-differentiation of cells 
in vitro is promising, as these acellular materials may not need additional exogenous cells or 
growth factors when implanted in vivo. If this simplistic approach is viable, it is attractive 
because it could reduce costs and potentially gain FDA approval more quickly. 
 
DISCUSSION 
The use of ECM and other raw materials are gaining popularity in the regenerative medicine 
field as an alternative to synthetic materials due to their two main advantages of becoming 
integrated (rather than degraded and removed) and providing bioactive cues to autologous cells. 
ECM plays an important role in native tissue function by providing mechanical stability to the 
tissue and signals, both mechanical and chemical, to the cells contained within the ECM. 
Because the ECM plays a large role in cell signaling and differentiation, in the case of cartilage 
ECM, it has the potential to act as a chondroinductive material. Decellularized tissues largely 
retain the native composition of the ECM and therefore have similar signaling effects on cells. 
Cartilage must be able to support high compressive loads and therefore the repaired tissue must 
have high compressive strength. The chemical composition of the regenerated cartilage is 
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extremely important in the compressive strength of the tissue as many of the ECM components 
such as the GAGs and collagen II recruit and trap water within the tissue. Future work is 
necessary to determine whether the structure or composition of the matrix is more important for 
chondroinductive effects.  
 Cartilage matrix in hyaline cartilage tissue engineering has shown that it has the capacity 
to help differentiate both ASCs and BMSCs into chondrocyte-like cells, as well as dedifferentiate 
dedifferentiated chondrocytes. Although cartilage matrix can promote a favorable response in 
vitro and no negative responses in vivo on tissue repair, future work needs to evaluate whether 
the DCC has chondroinductive effects on cartilage healing in vivo. Induction of tissue repair is 
particularly important in cartilage regeneration because of the tissue’s decreased ability to 
regenerate and repair itself, which is why successful cartilage regeneration has been cited as the 
most vexing problem in musculoskeletal medicine.83 
 Delivery of cartilage ECM materials must be considered to achieve the desired 
mechanical performance. Crosslinking cartilage matrix is a common method for creating 
scaffolds, but the effects of crosslinking on the chemical composition of the material have not yet 
been determined. The crosslinking creates a porous 3D scaffold that resists cell-mediated 
contraction. However, crosslinking may alter the matrix in ways that may slow or prevent its 
incorporation into the neocartilage, which may ultimately delay or prevent healing. Other 
scaffolding techniques such as combining with synthetic materials may be a promising avenue 
for delivery of cartilage matrix because the mechanical properties and 3D structure can be 
controlled.  
 We reiterate that it is important to distinguish between matrix derived from cell culture 
and matrix derived from native tissue, and to further categorize cartilage matrix into 
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decellularized and devitalized matrix.  Both CDM and native cartilage matrix have appealing 
qualities, however, tradeoffs when considering whether to use native cartilage or CDM should 
also be evaluated to direct the field. Using CDM may result in a greater ability to manipulate the 
structure of the scaffold by controlling the shape the matrix forms without additional 
crosslinking or other chemical modifications. On the other hand, native cartilage materials can be 
produced in much greater quantities in shorter amounts of time.  
 Additional work should explore the immunogenicity of cartilage only and osteochondral 
xenograft implants. Most immunogenicity research regarding decellularized tissue is focused on 
cardiovascular tissue implants. While the cardiovascular implant studies may help inform and 
direct the cartilage matrix field, more information about how the xenograft material acts in the 
osteochondral environment is needed. A few studies have reported successful removal of 
xenogeneic antigens following chemical decellularization, however, this critical decellularization 
endpoint is not considered globally in the field. The removal of this antigen has only been 
considered with chemically decellularized matrices and has not been explored in devitalized 
tissues. 
 Currently, the ability to obtain human tissues is more established and easier than 
obtaining animal tissues. The cost of the tissue retrieval process as well as the tissue processing 
after harvest must be considered.  The FDA approval process must also be considered; using 
allogeneic tissue may be more successful than xenogeneic tissue and approved more quickly 
because human tissue does not contain the alpha-Gal epitope and decellularization of the tissue 
would further decrease the immunogenicity by removing the donor cells. Native cartilage matrix 
and CDM may also suffer from insufficient supply for obtaining autologous or allograft tissue. 
Creating a viable business model and insurance reimbursement due to the need for multiple 
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surgical procedures may further complicate the use of autologous tissue for creation of CDM 
constructs. Currently, only DCC materials have been delivered to cartilage defect sites and are 
available on the market. Little is known about the FDA regulatory pathways CDM materials 
would follow and their efficacy in vivo.   
 In summary, cartilage matrix appears to be a promising material for hyaline cartilage 
tissue engineering applications. Native cartilage matrix and CDM are both ECM materials with 
established decellularization or devitalization techniques; however, at this time native cartilage 
matrix can be made in larger quantities in a short amount of time. To choose the most successful 
type of cartilage matrix for a particular application, we must decide if full decellularization is 
desired or if devitalization is acceptable. The source of the matrix, native or cell derived, must 
also be considered when designing the delivery construct as the chemical composition and 
mechanical properties of each type may differ greatly. FDA regulatory approval may affect the 
decision to use native or cell derived matrices as well as the type of processing the matrix 
undergoes. Most likely, for quicker approval, a full chemical decellularization of allogeneic 
matrix may be more successful because of the reduced antigenicity of the material due to both 
the removal of cells and no cross-species interactions. Insurance reimbursements are also an 
important consideration because route of delivery of the matrix must be designed in a way that 
reduces costs and performs as well as or better than current treatments. Cartilage matrix has been 
incorporated into different types of scaffolds including crosslinked, layered, and combination 
with other biomaterials, however; only one commercially available product consisting of 
decellularized cartilage exists at this time. Until clinical results are available, the success of this 
product is unknown. Other currently marketed products for cartilage repair have limitations such 
as cell viability and storage considerations that may be overcome through the use of acellular 
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matrices. The future of cartilage matrix must identify the effects of scaffold incorporation on the 
chemical composition of the matrix and define clear guidelines outlining the definition and limits 
of decellularization. Because previous work has identified cartilage matrix as being potentially 
chondroinductive, cartilage matrix may replace the need for more invasive surgical techniques to 
treat cartilage defects and arthritis.  
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CHAPTER 3: Decellularized Cartilage as a Chondroinductive Material for 
Osteochondral Tissue Engineering 
 
ABSTRACT 
 Extracellular matrix (ECM)-based materials are attractive for regenerative medicine in 
their ability to potentially aid in stem cell recruitment, infiltration, and differentiation without 
added biological factors. In musculoskeletal tissue engineering, demineralized bone matrix is 
widely used, but recently cartilage matrix has been attracting attention as a potentially 
chondroinductive material. The aim of this study was thus to establish a chemical 
decellularization method for use with articular cartilage to quantify removal of cells and analyze 
the cartilage biochemical content at various stages during the decellularization process, which 
included a physically devitalization step. To study the cellular response to the cartilage matrix, 
rat bone marrow-derived mesenchymal stem cells (rBMSCs) were cultured in cell pellets 
containing cells only (control), chondrogenic differentiation medium (TGF-β), chemically 
decellularized cartilage particles (DCC), or physically devitalized cartilage particles (DVC). The 
chemical decellularization process removed the vast majority of DNA and about half of the 
glycosaminoglycans (GAG) within the matrix, but had no significant effect on the amount of 
hydroxyproline. Most notably, the DCC group significantly outperformed TGF-β in 
chondroinduction of rBMSCs, with collagen II gene expression an order of magnitude or more 
higher.  While DVC did not exhibit a chondrogenic response to the extent that DCC did, DVC 
had a greater down regulation of collagen I, collagen X and Runx2. A new protocol has been 
introduced for cartilage devitalization and decellularization in the current study, with evidence of 
chondroinductivity. Such bioactivity along with providing the ‘raw material’ building blocks of 
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regenerating cartilage may suggest a promising role for DCC in biomaterials that rely on 
recruiting endogenous cell recruitment and differentiation for cartilage regeneration.  
 
INTRODUCTION 
Degeneration of articular cartilage can be caused by traumatic injury or arthritis. Articular 
cartilage regeneration is a particularly difficult problem because cartilage has a limited capacity 
for self-repair and low vascularity.18, 83 Current clinical treatments for cartilage degeneration 
include autologous chondrocyte implantation (ACI), mosaicplasty, microfracture, and allograft 
implants. These treatments have limited success in fully regenerating functional articular 
cartilage. The repair tissue is often fibrous with inferior mechanical performance compared to 
native cartilage.  
In the past, tissue engineering has aimed to regenerate articular cartilage utilizing 
synthetic biomaterials due to the ability to alter and control synthetic materials’ mechanical 
properties.84-86 These synthetic materials, however, have limited ability to recruit and 
differentiate stem cells without added biological components such as peptide sequences or 
growth factors. Recently, acellular extracellular matrix (ECM) materials have become popular 
because the matrices retain the native structure of cartilage, which provides cells with both 
mechanical and chemical signals to aid in stem cell differentiation and recruitment, and 
ultimately in tissue regeneration.1, 4, 6 ECM materials can induce differentiation and regeneration 
without additional biologic additives, which may be an attractive alternative from both cost and 
regulatory standpoints.31  
 ECM materials can be obtained from either cell-derived matrices secreted during in vitro 
culture (CDM) or from native tissue.1, 21, 24, 33, 47, 80 Both types of matrices have been either 
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decellularized to fully remove all cellular components and nucleic acids or devitalized to kill all 
remaining cells within the matrix without completely removing them. In contrast, fully 
decellularized native cartilage (DCC) tissue presents a unique challenge because the dense ECM 
makes full decellularization difficult due to diffusion limitations.15, 24 The tissue is often 
mechanically disrupted to increase the efficacy of chemical decellularization but destroys the 
mechanical properties of the matrix.21-23 The dense nature of native articular cartilage also 
restricts cell migration into the matrix.24 Successful decellularization results in an acellular 
matrix that has low immunogenicity with the same biochemical make-up as native cartilage.20, 24, 
26 Devitalized cartilage (DVC), on the other hand, may still contain antigenic cell surface 
markers. Both types of cartilage matrix can additionally be combined with synthetic biomaterials 
or crosslinked to achieve the desired mechanical properties or shape.45, 46  
 Previous studies have investigated the use of DCC and DVC as chondroinductive 
materials, but have not fully characterized the materials through the decellularization 
processes.20, 23, 33, 46, 54 Other studies have also chemically or physically crosslinked the DCC or 
incorporated the DCC into synthetic material scaffolds prior to in vitro cell culture. The cellular 
response to native, non-crosslinked DCC has not been investigated. Additionally, DCC has not 
been directly compared to devitalized native cartilage (DVC) in vitro.  
The primary goal of the current study was to assess changes to native cartilage matrix 
throughout both decellularization and devitalization protocols and to further investigate the 
chondroinductive potential of cartilage ECM materials. The current study investigated the 
combined physical and chemical decellularization and the physical devitalization of native 
porcine cartilage processing effects on the biochemical and DNA content of the material at 
different steps of the decellularization process. The chondroinductive nature of non-crosslinked 
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DCC were also examined for future use in cartilage tissue engineering by assessing the 
differentiation of rat bone marrow derived mesenchymal stem cells (rBMSCs) in 3D pellet 
culture without added growth factors.  
 
MATERIALS AND METHODS 
Tissue Retrieval, Decellularization, and Devitalization 
Ten porcine knee and hip joints were purchased from a local abattoir following sacrifice (120 kg, 
mixed breed, mixed gender) (Bichelmeyer Meats, Kansas City, KS). Articular cartilage from 
both the knee and hip joints was carefully removed and collected using scalpels. The cartilage 
was rinsed in phosphate buffered saline (PBS) and stored at -20°C. Following freezing, the 
cartilage was coarsely ground using a cryogenic tissue grinder (BioSpec Products, Bartlesville, 
OK). The coarsely ground tissue was packaged into dialysis tubing (3500 MWCO) packets for 
decellularization.  
Cartilage was devitalized following tissue harvest by immediately freezing at -20°C and 
then lyophililzing the tissue. The lyophilized tissue was then processed in a freezer-mill and 
frozen again at -20°C.  
The cartilage was decellularized using an adapted version of our previously established 
method using reciprocating osmotic shock, detergent, and enzymatic washes.87 Reagents were 
purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. All steps of 
decellularization were carried out under agitation (200 rpm) at 21°C unless otherwise noted. 
First, the cartilage packets were placed in hypertonic salt solution (HSS) overnight to disrupt 
membranes and lyse the cells. Following HSS treatment, the tissue was subjected to 2 cycles of 
reciprocating triton-X 100 (0.05% v/v) and HSS treatments to further breakdown cellular 
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membranes. The tissue was then treated with benzonase (0.0625 KU ml-1) overnight at 37°C to 
fragment nucleic acids. Sodium-lauroyl sarcosine (NLS, 1% v/v) was then used overnight to 
further solubilize and remove cells. Next, the tissue was washed with 40% ethanol, followed 
with organic exchange resins to remove all organic solvents. Lastly, the tissue was removed from 
the dialysis tubing packages and rinsed with deionized water before freezing.  
After decellularization, the tissue was lyophilized for 48 hours and cryo-ground into a 
fine powder with a freezer-mill (SPEX SamplePrep, Metuchen, NJ). Following cryo-grinding, 
the cartilage particles were sifted through size-specific meshes (350, 100, and 45 µm) to obtain a 
more homogenous particle size range.  
 
Tissue Decellularization and Devitalization Characterization  
 Decellularization analyses including quantification of remaining DNA, GAG, and 
hydroxyproline within the matrix, were performed on native hydrated, native frozen, native 
lyophilized, native cryo-ground (DVC), decellularized coarse ground, and decellularized cryo-
ground cartilage (DCC) (n=6).  
 
Scanning Electron Microscopy 
The size and morphology of DCC particles were observed using LEO 1550 field 
emission scanning electron microscopy (SEM). Prior to imaging, DCC particles were lyophilized 
and sputter-coated with gold.  
 
BMSC Harvest and Cell Seeding 
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 Rat bone marrow mesenchymal stem cells (rBMSC) were harvested from the femurs of 4 
male Sprague-Dawley rats (200-250 g) following a University of Kansas approved IACUC 
protocol. The BMSCs were cultured in minimum essential medium (MEM) α culture medium 
with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic (anti-anti) during expansion. 
At passage 4, the cells were suspended in MEM α culture media at 1x106 cells/mL. 1 mL of cell 
suspension was added to 25 mg of both DCC and DVC (no size exclusion) and centrifuged for 5 
minutes (n=5). The TGF-β and negative control groups contained 106 cells without additional 
material. Experimental and negative control groups were cultured in 1 mL of the medium used 
during expansion. The TGF-β control group was cultured in chondrogenic differentiation 
medium containing 10 ng/mL human recombinant TGF-β3 (PeproTech, Rocky Hill, NJ), 50 
µg/mL ascorbic acid, 1% Penicillin Streptomycin, 40 µg/mL L-proline, 100 µmol sodium 
pyruvate, 0.1 µm dexamethasone, 1% insulin-transferrin-selenium 100X (ITS), and 1% non-
essential amino acids (NEAA). The medium was changed every 48 hours.  
 
Biochemical Analysis 
 The biochemical content of the cartilage was assessed after each processing step: native 
cartilage harvest, coarse grinding, decellularization, and cryo-grinding (n=6). The DNA content 
was also assessed at day 1 and 7 of pellet culture (n=5). Prior to biochemical analysis, all tissue 
samples were digested in a papain solution for 24-48 hours.  
 Biochemical content was measured as previously reported.29, 88, 89 Briefly, 
glycosaminoglycan (GAG) content was measured with a dimethylmethylene blue (DMMB) 
assay kit (Blyscan, Westbury, NY). Total hydroxyproline content was measured using a 
commercially available hydroxyproline detection kit (Sigma, St. Louis, MO). Double-stranded 
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DNA was detected using a high sensitivity PicoGreen assay kit (Molecular Probes, Eugene, OR). 
All assay kits were used in accordance with each manufacturer’s guidelines.  
 
Gene Expression  
 RNA was isolated and purified from cells using the Qiagen RNeasy mini kit (Valencia, 
CA). All RNA samples were reverse transcribed using a high capacity cDNA reverse 
transcription kit (Invitrogen, Carlsbad, CA). Real-time quantitative polymerase chain reaction 
(qPCR) was performed using a RealPlex MasterCycler (Eppendorf, Hauppauge, NY) and 
TaqMan gene expression assays using equal concentrations of DNA for each sample. Rat 
specific Col2A1, Col1A1, Runx2, Sox9, Col10A1, Acan, and GAPDH commercially available 
primers were used (Invitrogen, Carlsbad, CA). The 2-∆∆Ct method was used to determine the 
relative expression of each gene with GAPDH used as an endogenous control.90, 91  
 
Statistical Analysis 
Results are reported as a mean ± standard deviation. SPSS statistical software was used to 
construct boxplots to remove outliers prior to performing statistical analyses. All statistical 
analyses were performed using a one way analysis of variance (ANOVA) and Tukey’s post-hoc 
tests. Significance was determined for p<0.05.  
 
RESULTS  
Tissue Decellularization and Processing 
Following coarse grinding, chemical decellularization, and cryo-grinding there was an 
86% reduction in DNA content (p<0.01) (Fig. 3.1) and a 55% reduction in GAG content 
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(p<0.01) (Fig. 3.2). However, there was no significant difference in hydroxyproline content 
during any steps of the tissue processing (Fig. 3.3). Freezing, lyophilization, and cryo-grinding 
had no significant effect on DNA or GAG content in the tissue. 
SEM Imaging 
 SEM imaging revealed that size exclusion filtering was successful at achieving a more 
homogenous cartilage particle size population (Fig. 3.5).  
 
Cell Viability  
 DNA was quantified in cell pellets at 0 and 7 days to determine cell proliferation on 
devitalized and decellularized cartilage. All cell pellets showed a significant increase in DNA 
amount over 7 days (p<0.05) (Fig. 3.4). At 7 days, cell pellets with DCC had approximately 40% 
more DNA than the DVC cell pellets at the same time (p<0.01) (Fig. 3.4). DCC pellets also had 
approximately 30% more DNA than the negative control group (p<0.01) (Fig. 3.4).  
 
Gene Expression 
 
qPCR was used to determine the expression of both chondrogenic and osteogenic genes. 
DCC pellet group gene expression showed over a 90% increase in collagen II expression 
compared to both the TGF-β and negative control groups at day 1 (p<0.01) (Fig. 3.6). Collagen 
II expression remained greater than both the TGF-β and negative control groups at day 3 
(p<0.01). The DCC pellet group also showed 75% greater upregulation of Sox9 compared to the 
TGF-β group at day 0 (p<0.01) (Fig. 3.6). A 60% increase in aggrecan expression was observed 
in the DCC group compared to the negative control at day 1 (p<0.01) (Fig. 3.6). The osteogenic 
marker collagen X was expressed 5 times greater in the DCC group compared to the negative 
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control group at day 7 (p<0.01) (Fig. 3.6). Collagen X was also expressed 45 times greater in 
DCC than in the TGF-β group (p<0.01). Runx2 expression in the DCC group was also 
upregulated compared to the negative control group by 75% at day 7 (p<0.05) (Fig. 3.6). 
Collagen I expression in the DCC group was also over 50% greater than both the negative 
control and TGF-β groups at day 1 (p<0.01), but significantly decreased at both days 3 and 7 
compared to day 1 (p<0.05) (Fig. 3.6).   
 The DVC group saw no significant difference in collagen II expression from both the 
negative control and TGF-β groups at days 1 and 3 (Fig. 3.6). Aggrecan expression in the DVC 
group was over 40% greater than both the TGF-β and negative control groups at day 7 (p<0.05), 
however, it was not statistically significant from the DCC group at the same time (Fig 3.6). The 
DVC group Sox9 expression increased approximately 30% between days 3 and 7 (p<0.05) but 
was not significantly greater than either control group or the DCC group (Fig. 3.6). Expression of 
osteogenic marker collagen X was 100% less in the DVC group compared to the DCC group at 
day 7 (p<0.01) (Fig. 3.6). Runx2 expression was also 30% less in the DVC group compared to 
the DCC group at day 7 (p<0.01) (Fig. 3.6). Collagen I expression in the DVC group was 60% 
less than the DCC group at day 1 (p<0.01) and 3 times less than the TGF-β group at day 7 
(p<0.05) (Fig. 3.6).  
 
DISCUSSION 
 Synthetic biomaterials have achieved clinically relevant mechanical performance for 
osteochondral implantation; however, they have not been successful at fully regenerating 
functional articular cartilage. The use of ECM-based materials for osteochondral tissue 
engineering is a promising avenue because of the ECM materials’ ability to mimic the native 
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cartilage environment by providing cells with adhesion sites and biochemical signals that aid in 
recruiting and differentiating stem cells for tissue regeneration. ECM-based materials may be 
able to provide these signals to cells without manipulation of the material with added biological 
factors (e.g., growth factors or adhesion peptides).  
Successful decellularization of articular cartilage has previously been accomplished using 
different methods with differing results with respect to the remaining biochemical content, cell 
removal, and mechanical performance.19, 20, 31, 32 Cartilage ECM has also been used as a 
scaffolding material that has only been physically devitalized as opposed to being decellularized. 
The different effects that devitalization vs. decellularization have on the cartilage matrix until 
now have not been fully characterized throughout each respective process. Moreover, DVC and 
DCC have not been directly compared in vitro or to a positive control such as TGF-β. The 
current study has shown that DCC may outperform both DVC and TGF-β at inducing 
chondrogensis in BMSCs in vitro.  
The current combined physical and chemical decellularization method was successful at 
reducing the amount of detectable dsDNA within the cartilage matrix by 86% (p<0.01). 
Freezing, lyophilization, and cryo-grinding, all common devitalization techniques, as expected 
were not effective at removing any dsDNA from the matrix. Although the DNA content of the 
DCC was significantly reduced, the GAG content was also significantly reduced by 55% (Fig. 
3.2).  
Currently, little is understood about the mechanism by which cartilage matrix materials 
induce chondrogenesis in vitro. Retention of GAG within the matrix may be beneficial for 
chondroinduction based on previous studies citing that GAGs such as chondroitin sulfate and 
aggrecan may have chondroinductive effects in vitro.29, 30, 92 Although GAG retention may be 
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beneficial for cell signaling, a partial reduction in GAG content may be beneficial to create a less 
dense matrix that allows for cell infiltration and migration.24  
In the current study, BMSCs cultured with DCC showed increased expression of both 
chondrogenic and osteogenic gene markers compared to the negative control group. The DVC 
group showed lower expression of the osteogenic markers collagen X and Runx2 than the DCC 
group. Although the DVC seemed to limit osteoinduction in the BMSCs, the chondrogenic gene 
markers collagen II, aggrecan, and Sox9 were significantly upregulated in the DCC group 
compared to the DVC group. This suggests that chondroinduction by DCC is not affected by the 
decellularization method.  Additionally, comparison between chondroinduction via TGF-β and 
DCC showed that DCC chondroinduction was not statistically significant with respect to 
expression of aggrecan and Runx2 at all time points. Chondroinductive markers including 
collagen II and Sox9 were expressed 20 and 4 times higher respectively in the DCC group 
compared to the TGF-β group at day 1. Similar expression of collagen I between the DCC group 
and the TGF-β group was also seen at 3 and 7 days. These results suggest that DCC may 
outperform TGF-β at inducing chondrogenesis but does not confirm that latent TGF-β within the 
DCC matrix is responsible for the observed chondrogenesis.  
Physical size exclusion filtering was also successful at achieving a more homogenous 
size distribution of cartilage particles compared to the unfiltered DCC particles (Fig. 3.5). The 
ability to control the size distribution of the cartilage particles may be beneficial when 
considering incorporation of cartilage particles into scaffolds either via crosslinking or 
combination with synthetic materials in the future, however, size distribution was not specifically 
investigated in the current study.  
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It is still unclear whether full decellularization of articular cartilage is necessary when 
delivering cartilage matrix materials to osteochondral defects in vivo. Decellularization may 
reduce the antigenicity of the matrix by removing cellular materials that have been previously 
shown to elicit immune responses such as human leukocyte antigens (HLA) and the alpha-Gal 
epitope. Previous studies have shown successful removal of the alpha-Gal epitope through 
chemical decellularization but not physical devitalization alone.24  
Although not specifically explored in the current study, a delivery method of this material 
must also be considered to create a tissue engineering scaffold with that contains both the 
benefits of cartilage matrix materials with enhanced mechanical performance. The development 
of an acellular, non-biologically modified biomaterial that has the ability to induce 
chondrogenesis is of particular importance to the tissue engineering field because of it may have 
the ability to replace current surgical techniques with more positive outcomes. The ECM 
material approach is also highly attractive from both a regulatory and commercialization 
standpoint because of the cost of materials and no added biologic factors.  
 This is the first study to fully characterize both DCC and DVC through the respective 
decellularization and devitalization processes. Addtionally, this is the first study to directly 
compare the bioactivity of non-crosslinked DCC, DVC, and TGF-β in vitro. DCC was found to 
have superior effects compared to both DVC and TGF-β at inducing chondrogensis and 
supporting cell proliferation. The ability to influence cell differentiation without additional 
biological manipulation makes DCC a promising biomaterial for use in future cartilage tissue 
engineering applications.    
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CHAPTER 4: Bioactive Microsphere Based Scaffolds Containing 
Decellularized Cartilage  
 
ABSTRACT 
 The aim of this study was to fabricate mechanically functional microsphere-based 
scaffolds containing decellularized cartilage (DCC), with the hypothesis that this approach would 
induce chondrogenesis of rat bone marrow derived mesenchymal stem cells (rBMSCs) in vitro. 
The DCC was derived from porcine articular cartilage and fully decellularized using a 
combination of physical and chemical methods. Four types of scaffolds were fabricated: 
Poly(D,L-lactic-co-glycolic acid) (PLGA) only (negative control), TGF-β encapsulated (positive 
control), PLGA surface coated with DCC, and DCC-encapsulated. These scaffolds were seeded 
with rBMSCs and cultured up to 6 weeks. The compressive modulus of the DCC-coated 
scaffolds prior to cell seeding was significantly lower than all other scaffold types. Gene 
expression was comparable between DCC-encapsulated and TGF-β encapsulated groups. 
Notably, DCC-encapsulated scaffolds contained 70% greater amount of GAG and 85% more 
hydroxyproline compared to the TGF group at week 3 (with baseline levels subtracted out from 
acellular DCC scaffolds). Certainly bioactivity was demonstrated in eliciting a biosynthetic 
response from the cells with DCC, although true demonstration of chondrogenesis remained 
elusive under the prescribed conditions. Encapsulation of DCC appeared to lead to improved cell 
performance relative to coating with DCC, although this finding may be a dose-dependent 
observation. Overall, DCC introduced via microsphere-based scaffolds appears to be promising 
as a bioactive approach to cartilage regeneration, although additional studies will be required to 
conclusively demonstrate chondroinductivity. 
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INTRODUCTION 
Articular cartilage has limited capability for self repair after traumatic injury or 
osteoarthritis. Self-repair is limited in part because of the dense extracellular matrix (ECM), 
sparse chondrocyte population, and reduced access to systemic circulation. Current clinical 
treatments include osteochondral transplantation (mosaicplasty), autologous chondrocyte 
implantation (ACI), and microfracture.3, 18 These current treatment options may produce inferior 
repair cartilage with respect to mechanical performance, tissue reintegration, and composition.26, 
33 They also have additional associated risks such as donor site morbidity and the need for 
multiple surgical procedures. Recently, acellular biomaterials have gained much popularity in the 
tissue engineering field due to the potential to create an off the shelf product with characteristics 
that aid in repairing cartilage tissue by enhancing stem cell recruitment, infiltration, and 
differentiation.1, 4 One such material in particular, decellularized native cartilage (DCC) may be 
beneficial as it contains similar biochemical content as native cartilage and current problems 
associated with allograft implants (i.e., long term storage and immunogenicity) are mitigated.24, 
71, 72, 93 Previous studies have reported adipose derived stem cell (ASC) and bone marrow-derived 
mesenchymal stem cell (BMSC) differentiation in the presence of DCC.23, 33, 38 
 One drawback of DCC-based scaffolds is the mechanical function of the scaffolds is 
often compromised during the decellularization process.24, 26, 31 To help fabricate a material with 
desired compressive strength as needed for articular cartilage repair, combining DCC with a 
polymeric scaffold has previously been shown to achieve greater mechanical performance than 
DCC scaffolds alone.46 Using cartilage matrix to coat polymeric based scaffolds has also been 
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investigated previously with electrospun scaffolds but instead of using native cartilage, cell-
derived cartilage matrix (CDM) secreted in vitro was used.40  
 The difference between native derived (DCC) and CDM must be made, as the matrices 
may vary in both composition and mechanical performance. Decellularization efficiency may be 
greater in CDM because the matrix is less dense, but the material may not contain the same 
composition as native cartilage ECM. DCC was chosen for use in this study for the ease of 
acquiring the material and the ability to fully decellularize the tissue while maintaining 
biochemical content similar to native cartilage ECM.  
 Microsphere-based scaffolds for osteochondral tissue engineering are an attractive 
delivery vehicle for DCC due to the ability to control the morphology of the microspheres and, in 
turn, the properties of the bulk scaffold.92, 94 The polymeric material can also be selected for 
desired degradation and release rates of a wide variety of encapsulated materials.89, 95-97 
Previously, “raw materials” have been encapsulated in Poly(D,L-lactic-co-glycolic acid) (PLGA) 
microspheres that aided in BMSC differentiation and proliferation.92 DCC, however, has never 
previously been incorporated into microsphere-based scaffolds.  
 In the present study, we investigated the encapsulation of DCC in PLGA microsphere 
based scaffolds and the coating of the surface of PLGA microsphere scaffolds.  Our hypothesis 
was that the DCC material would aid in chondrogenic differentiation of BMSCs in vitro. 
 
MATERIALS AND METHODS 
Materials 
All reagents for decellularization were purchased from Sigma Aldrich (St. Louis, MO) 
unless otherwise noted. PLGA (50:50 D, L-PLGA with acid end group, intrinsic viscosity 0.40-
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0.50 dL/g) was purchased from Lakeshore Biomaterials (Birmingham, AL). Human recombinant 
TGF-β3 was purchased from PeproTech (Rocky Hill, NJ). 10 porcine knee and hip joints were 
obtained from crossbreed hogs (Cheshire White, Yorkshire, Berkshire, Duroc, Landrace, and 
Hampshire) with an approximate average mass of 120 kg. The joints were purchased from a local 
abattoir following sacrifice (Bichelmeyer Meats, Kansas City, KS).  
 
Tissue Harvest and Decellularization 
Articular cartilage was collected from joint surfaces using scalpels and immediately rinsed 
in phosphate buffered saline (PBS). PBS was drained from the material and cartilage was stored 
at -20°C until further use. Decellularization of the cartilage was performed using a protocol 
adapted from Converse et al.87 The cartilage was first coarsely ground using a cryogenic tissue 
grinder (BioSpec Products, Bartlesville, OK). Following additional freezing at -20°C, the 
cartilage particles were packaged into dialysis tubing (3500 MWCO) and stored in hypertonic 
salt solution (HSS) overnight at 21°C with gentle shaking (70 rpm). All subsequent steps were 
performed at 21°C under agitation (200 rpm) unless otherwise noted. The tissue was then subject 
to two reciprocating washes of triton X-100 (0.01% v/v) followed with HSS. Overnight, the 
tissue was treated with benzonase (0.0625 KU ml-1) to fragment nucleic acids at 37°C. Next, the 
tissue was treated with sodium-lauroylsarcosine (NLS, 1% v/v) overnight. Following NLS, the 
tissue was washed with ethanol (40% v/v). The tissue was then subjected to organic exchange 
resins to extract the organic solvents. Lastly, the tissue was washed in saline-mannitol solution 
(SMS). Following decellularization, the cartilage tissue was rinsed with deionized water and 
stored at -20°C. After freezing, the tissue was lyophilized and cryo-ground in a freezer-mill 
(SPEX Sample Prep, Metuchen, NJ).  
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Microsphere and Scaffold Fabrication 
Three types of microspheres were produced (1) PLGA only (PLGA) (negative control), (2) TGF-
β3 encapsulated (TGF) (positive control), and (3) solubilized DCC encapsulated (DCC-
encapsulated). All microspheres were fabricated using the patented precision particle formation 
method.17, 21, 23, 24 Microspheres were approximately 350-400 µm in diameter.  
 PLGA microspheres were fabricated at 20% w/v. DCC microspheres were fabricated by 
first solubilizing the DCC in an acid-pepsin solution for 24 hours. The acid pepsin solution 
contained 0.1 M HCl, 20 mg DCC / 1 mL HCl, and 1 mg pepsin / 1 mL HCl (pH = 5) (Sigma 
Aldrich, St. Louis, MO). After the solubilization period, the pH of the solution was raised by 
adding one-tenth the solubilized solution volume of 1 M NaOH and one-tenth the final solution 
volume of 10x PBS (pH = 8).25 The solubilized solution was then frozen and lyophilized. The 
solubilized DCC was added to a PLGA solution at 10% w/w.  
TGF-β was reconstituted in 10 mM citric acid TGF microspheres were created with a 
concentration of 30 µg TGF-β3 / g PLGA.17, 23  
 Scaffolds were fabricated as previously described.17, 21, 26 Briefly, microspheres were first 
loaded in a glass cylindrical mold. A 10 µm filter was used at the bottom of the mold and DI 
H2O was pulled through the mold by a vacuum pump. The microspheres were sintered together 
in a 95% v/v ethanol-acetone solution for 45 minutes. DCC-coated PLGA scaffolds were created 
using PLGA scaffolds (from PLGA-only microspheres). The PLGA scaffolds were placed in the 
DCC acid-pepsin solution for 3 minutes and the pH was adjusted to neutral by adding 1 M 
NaOH. The scaffolds were then lyophilized. Following sintering, the scaffolds were lyophilized. 
All scaffolds were sterilized with ethylene oxide prior to cell seeding. Additionally, acid treated 
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scaffolds were created for mechanical testing purposes. PLGA scaffolds were exposed to an 
acidic HCl solution (pH = 5) for 3 minutes and then lyophilized to mimic the effects of the acid-
pepsin solution the scaffolds were exposed to during the DCC-coating process.  
 
Cell Isolation and Culture 
Following a University of Kansas approved IACUC protocol, BMSCs were isolated from 
the femurs of 4 male Sprague-Dawley rats (200-250 g). Cells were isolated from the femurs by 
flushing the bones with cell culture media and immediately transferring the isolated bone 
marrow to tissue culture flasks. During expansion, the BMSCs were cultured in minimum 
essential media (MEM) alpha with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic 
(anti-anti). The BMSCs were expanded to passage 4 and suspended in cell culture media at a 
concentration of 12 x 105 cells/mL and 40 µL of cell suspension was pipetted onto constructs at 1 
x 107 cells/cm3 (500,000 cells/scaffold). After cells were seeded on scaffolds, the scaffolds were 
placed in the incubator for 1 hour to allow the cells to attach before adding culture media. The 
cell seeded scaffolds were cultured in medium containing high glucose DMEM, 1% insulin-
transferrin-selenium 100X (ITS), 50 µg/mL ascorbic acid, 40 µg/mL L-proline, 1% penicillin-
streptomycin, 0.1 µM dexamethasone, 25 mM HEPES buffer, 1% non-essential amino acids 
(NEAA), and 100 µM sodium pyruvate.  
 
SEM Imaging and Energy Dispersion Spectroscopy 
 Microspheres were imaged with a LEO 1550 scanning electron microscope (SEM) to 
observe the morphology of the microsphere surfaces. All microspheres were sputter-coated with 
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15 nm gold. The presence of nitrogen on the surface of the DCC-encapsulated microspheres was 
detected by SEM using energy dispersive spectroscopy (EDS) at 10 kV.  
 
Biochemical Content Analysis 
 Biochemical content analysis was performed on solubilized DCC, acellular scaffolds, and 
cell seeded scaffolds (n=5). For all analyses day 0 samples were collected at 24 hours. The 
biochemical content of the cell-seeded scaffolds was measured at 0, 3, and 6 weeks. Acellular 
scaffolds matched each time point and were used to subtract base values for all biochemical 
content. All samples were digested in 1 mL of papain solution containing 125 µg/mL papain, 
5mM N-acetyl cysteine, 5mM ethylenediaminetetraacetic acid (EDTA), and 100 mM PBS.29, 88, 
89  
 Biochemical content was measured as previously described.29, 88, 89 Briefly, double 
stranded DNA content was measured with the PicoGreen assay (Molecular Probes, Eugene, OR). 
The assay was performed according to the manufacture’s instructions. Sulfated 
glycosaminoglycan (GAG) content was measured with the dimethylmethylene blue (DMMB) 
assay (Blyscan, Westbury, NY) according to the supplier’s protocol. Total hydroxyproline 
content was measured with the Sigma Aldrich commercially available hydroxyproline assay kit 
(St. Louis, MO).  
 
DCC Release Analysis 
 Acellular DCC-encapsulated and DCC-coated were cultured in the same conditions as 
cell seeded scaffolds. The scaffolds were used to determine the remaining amount of GAG and 
hydroxyproline as described above. The amount of GAG and hydroxyproline content in acellular 
scaffolds was used to approximate the release of the DCC from the scaffolds.    
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Mechanical Testing 
 Uniaxial unconfined compression testing was performed on acellular scaffolds (n=4-5) 
with a custom-built compression-bath assembly in an Instron 5848 microtester (Norwood, 
MA).28 PLGA, TGF, DCC-coated, DCC-encapsulated, and acid treated scaffolds were tested. 
Following a tare load of 0.01 N samples were compressed at a strain rate of 10%/min in PBS at 
37 °C.  The compressive modulus was calculated from the linear region of the stress-strain curve.  
 
Gene Expression Analysis 
Gene expression analysis was performed at 0, 1.5, 3, and 6 weeks (n=5). Day 0 was 
defined as 24 hours following cell seeding. RNA was isolated and purified with the Qiagen 
RNeasy kit following provider recommendations (Valencia, CA). RNA was reverse-transcribed 
using a high capacity reverse transcriptase kit (Invitrogen, Carlsbad, CA). RT-PCR was 
performed with a RealPlex thermocycler (Eppendorf, Hauppauge, NY) and TaqMan gene 
expression assays (Invitrogen, Carlsbad, CA). All primers were commercially available and 
purchased from Invitrogen. Gene expression analysis was performed for both chondrogenic and 
osteogenic gene markers including Coll1A1, Coll2A1, Aggrecan, Sox9, and Runx2. GAPDH 
was used as an endogenous control. All results are reported as relative expression to GAPDH 
using the 2-ΔΔCt method.88, 102  
 
Immunohistochemistry Staining 
 
 Immunohistochemistry (IHC) was performed on week 3 DCC-encapsulated scaffolds. 
The scaffolds were fixed in 10% formalin and embedded in optimal cutting temperature (OCT) 
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medium (Tissue-Tek, Torrance, CA). 10 µm thick sections were cut using a cryostat (Micron 
Hm-500 OMP, Vista, CA). Primary antibodies for collagen I, collagen II, and aggrecan were 
obtained from Abcam (Cambridge, MA). Following the primary antibodies, biolynated 
secondary antibodies were used followed with the ABC complex (Vector Labratories, 
Burlingame, CA). The antibodies were visualized with the DAB substrate per the manufacturer’s 
protocol. Both cell-seeded and acellular scaffolds were stained.  
 
Statistical Analysis 
 All results are reported as mean ± standard deviation. Boxplots were created to remove 
all statistical outliers. Statistical analyses were performed using one way analysis of variance 
(ANOVA) and Tukey’s post-hoc tests. Significance was reported for p<0.05. SPSS statistical 
software was used for all analyses (Armonk, NY).  
 
RESULTS 
Microsphere Morphology  
 PLGA microspheres had a smooth, even surface without any pores (Fig. 4.1). TGF 
microspheres showed small pores on the surfaces. The DCC microspheres also had numerous 
small pores on the surface. The presence of nitrogen was used to indicate the presence of amino 
acids in the material. EDS showed that nitrogen was present in low amounts on the surface of the 
DCC-encapsulated microspheres (Fig. 4.2) revealing that the DCC was dispersed throughout the 
microspheres and near the surface.  
 
Biochemical Analysis 
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Dry SDCC contained 42.6±2.6 µg GAG/mg prior to incorporation into scaffolds. Acellular 
scaffolds were used to determine the remaining GAG and hydroxyproline content in the DCC 
and coated scaffolds. At time 0, the acellular DCC scaffolds contained nearly 4 times as much 
GAG as the coated scaffolds (p<0.001) (Fig. 4.3). The DCC group showed an approximately 
50% decrease in GAG content from day 0 to week 3 (p<0.001) (Fig. 4.3). After week 3, the 
GAG content remained roughly equal through week 6 in DCC-encapsulated scaffolds (no 
significant difference). The hydroxyproline content in the DCC-encapsulated scaffolds was 
approximately 10 times greater in the DCC-encapsulated group than in the DCC-coated group at 
day 0 (p<0.001). The DCC-encapsulated scaffold hydroxyproline content remained similar 
between weeks 3 and 6. Relative GAG loss in both DCC-encapsulated and DCC-coated scaffolds 
was similar by week 6 (Fig. 4.4).  
At day 0, the cell seeded DCC-coated scaffold group had approximately 30% more DNA 
than all of the other groups at all times (p<0.001) (Fig. 4.5). By week 3, all of the groups had 
similar amounts of DNA and remained constant through week 6 at approximately 3.5 µg 
DNA/scaffold. Since there were no statistically significant differences in DNA content other than 
the day 0 DCC-coated group, the HYP and GAG totals were reported on a basis of total content 
per scaffold. 
 The DCC-encapsulated scaffolds contained more hydroxyproline than both the blank and 
TGF scaffolds at day 0 and week 3, even with baseline values subtracted out from acellular 
scaffolds (p<0.001) (Fig. 4.6). The DCC-encapsulated group had nearly 7 times as much 
hydroxyproline compared to the blank group at day 0 (p<0.001). Additionally, the DCC-
encapsulated group had almost 10 times as much hydroxyproline than the TGF group at day 0 
(p<0.001). At week 3, DCC-encapsulated scaffold group contained approximately 8 times the 
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amount of hydroxyproline compared to TGF scaffolds and 40 times the amount of 
hydroxyproline compared to PLGA scaffolds (p<0.001). Following week 3, DCC-encapsulated 
scaffolds exhibited a significant reduction in the amount of hydroxyproline/scaffold (p<0.005). 
There was no significant change in hydroxyproline content in the DCC-coated scaffolds. At 
week 6 the DCC-encapsulated group had over 10 times as much hydroxyproline as the blank 
group (p<0.05).  
In blank, DCC-encapsulated, and DCC-coated cell seeded scaffolds the GAG content 
significantly decreased between weeks 3 and 6 (p<0.001) (Fig. 4.6). Similar trends were seen 
between GAG and hydroxyproline content, i.e. decreased amount of biochemical content at week 
6 compared to week 3. DCC-encapsulated scaffolds had significantly greater GAG and 
hydroxyproline content at 3 weeks compared to day 0 values and TGF group at the same times 
(p<0.001). However, at week 6, the hydroxyproline content of the DCC-encapsulated scaffolds 
significantly decreased by 70% and the GAG content decreased by 65% from the week 3 values 
(p<0.005). 
 
Mechanical Testing 
 The blank, TGF, and DCC-encapsulated scaffolds groups at week 0 had compressive 
elastic moduli around 80 kPa that were not significantly different from one another. However, 
the DCC-coated group compressive elastic modulus was approximately 75% less than all other 
groups (p<0.05) (Fig. 4.7). Additionally, the acid treated scaffolds were not statistically 
significant from the blank scaffolds or the DCC-coated scaffolds.  
 
Gene Expression 
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At day 0, the TGF group had over 3 times greater expression of collagen II than the DCC 
group, however, there was no statistical significance (Fig. 4.8). The TGF group had nearly 16 
times the expression of collagen II compared to the blank group at day 0 (p<0.001). There was 
no statistically significant difference between collagen II expression in the DCC-encapsulated 
group and TGF group. The DCC-coated groupo had significantly less expression than the TGF 
group at day 0 (p<0.001). After day 0, no group showed expression of collagen II.  
At day 0, day 10, and week 3, the DCC-encapsulated group had similar expression of 
Sox9 compared to the blank group. Additionally, the DCC-encapsulated group had similar 
expression of Sox9 as the TGF group at day 10 and week 3. At day 0, the TGF group had nearly 
3 times the expression of Sox9 compared to the DCC-coated group (p<0.001).  
 There were no statistically significant differences in aggrecan expression among groups 
at any time point. However, it was worth noting that the aggrecan expression in the blank group 
decreased 87% at week 3 compared to days 0 and 10 (p<0.01).  
 Both TGF and DCC-encapsulated groups had nearly 80% less expression of Collagen I at 
day 0 compared to the blank and DCC-coated groups (p<0.001). At day 0, the blank group had 
2.5 times greater expression of Runx2 compared to the TGF group (p<0.001). There was no 
significance among the TGF, DCC-coated, and DCC-encapsulated groups with respect to Runx2 
expression.  
 
Immunohistochemistry Staining 
 
 IHC staining of week 3 DCC-encapsulated scaffolds was positive for collagen II, 
collagen I, and aggrecan (Fig. 4.9). Collagen I staining was more intense in the cell-seeded DCC-
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encapsulated scaffolds compared to the acellular DCC-encapsulated scaffolds. Collagen II and 
aggrecan staining were nearly equal between cell-seeded and acellular scaffolds at week 3.  
 
 
DISCUSSION 
 In the current study, DCC was incorporated into microsphere-based scaffolds either by 
coating PLGA microsphere scaffold surfaces or by encapsulating the DCC within PLGA 
microspheres. Although cellular response characterization to the DCC in the microsphere-based 
scaffolds did not overwhelmingly indicate chondrogenesis in BMSCs, the DCC material did 
induce some bioactivity to the cells. The difference between the loading amounts achieved by 
different DCC incorporation methods (coating vs. encapsulating) may have contributed to the 
difference in cellular responses to the respective scaffold types as the acellular DCC-
encapsulated scaffolds contained significantly greater amounts of GAG and hydroxyproline than 
the acellular DCC-coated scaffolds. The processing of the DCC material in both DCC-coated and 
DCC-encapsulated groups was the same, however, the presentation of the material to the BMSCs 
was different and may have also contributed to differences between the coated and encapsulated 
groups. The DCC-encapsulated group relied more greatly on diffusion of the DCC out of PLGA 
microspheres even though there was a small amount of nitrogen present on the surface of the 
DCC-encapsulated microspheres. The DCC-coated group was available for cells on the surface 
of the scaffolds and did not rely on diffusion out of porous microspheres.  
A benefit to the microsphere-based scaffolds and encapsulation technique used in the 
study was that the DCC-encapsulated scaffolds had comparable mechanical properties to the 
PLGA scaffolds. The DCC-coated scaffolds, however, had a significantly reduced compressive 
modulus compared to all other scaffold types. The decrease in mechanical performance of the 
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DCC-coated scaffolds may have been partially due to the coating procedure and exposure to acid 
as the acidic conditions could increase the rate of degradation of the PLGA. The acid treated 
scaffolds were not statistically significant from any other type of scaffold. Previous studies have 
reported decreased mechanical properties in cartilage matrix-polymer constructs compared to 
polymer only constructs.14, 30    
 The porous morphology of the microspheres allowed for diffusion of both TGF-β and 
DCC out of the respective scaffold types. Based on quantification of remaining hydroxyproline 
and GAG content in acellular scaffolds, by week 6, the remaining GAG content reduced by 50% 
and the remaining hydroxyproline content reduced by 75% in the DCC-encapsulated scaffolds.  
At week 6, the total hydroxyproline and GAG content in cell-seeded DCC-encapsulated 
scaffolds also significantly decreased compared to previous time points. Additionally, at week 3, 
chondrogenic gene markers Sox9, aggrecan, and collagen II all decreased in the DCC-
encapsulated group. The decrease in chondrogenic gene markers at week 3 in the DCC-
encapsulated scaffold group was consistent with the more intense staining of collagen I at week 3 
in the DCC-encapsulated scaffolds. However, although chondrogenic gene markers decreased at 
week 3, collagen I and the osteogenic marker Runx2 remained low and not statistically 
significant from that of the TGF group. At all gene expression time points, the DCC-
encapsulated scaffolds did not differ significantly from the TGF group. Hydroxyproline content 
was greater in DCC-encapsulated constructs at all time points compared to the TGF scaffolds. 
The GAG content was also greater in DCC-encapsulated scaffolds than in TGF scaffolds at day 0 
and week 3. These higher biochemical contents in the DCC-encapsulated group may suggest that 
the encapsulated DCC was as effective as TGF-β at inducing chondrogenesis in BMSCs. Once 
less than half of the originally encapsulated DCC remained in the scaffolds, a decrease in GAG 
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and hydroxyproline production rate was observed as well as a decrease in chondrogenic gene 
markers. The significant reduction in remaining DCC encapsulated within the scaffoldssuggests 
that the bioactivity that was observed through week 3 was due to the encapsulated DCC.  
 Prior to cell seeding, the DCC-encapsulated scaffolds contained nearly 5 times as much 
GAG and 10 times as much hydroxyproline as the DCC-coated scaffolds. Both types of scaffolds 
in the absence of cells saw a significant reduction in both GAG and hydroxyproline content at 
week 3. Although the rate of biochemical content loss was nearly equal, at weeks 3 and 6 the 
DCC-encapsulated scaffolds still contained 10 times as much hydroxyproline and 5 times as 
much GAG as the DCC-coated scaffolds. The differences in the amount of DCC material did not 
have an effect on the amount of cells within the scaffolds except at day 0, when the DCC-coated 
scaffolds had a significantly greater amount of DNA than all other scaffolds. The greater amount 
of DNA may be due to the immediate exposure to DCC, which may contain cellular adhesion 
sites to aid in cell attachment and migration. The difference in amount of DCC material between 
the DCC-coated and DCC-encapsulated scaffolds also affected the total amount of GAG and 
hydroxyproline in cell-seeded scaffolds. At all time points, DCC-encapsualted scaffolds 
contained significantly greater amounts of hydroxyproline and GAG compared to the DCC-
coated scaffolds. The DCC-coated scaffolds exhibited no clear trend of chondrogenesis or 
osteogensis compared to TGF scaffolds at day 0. However, by week 6, DCC-coated, DCC-
encapsulated, and TGF groups had equal expression of all genes (chondrogenic and osteogenic). 
Most significant differences among groups with respect to gene expression were observed at 
days 0 and 10.  
 The mechanism by which DCC induces chondrogenesis is still unclear at this time. In the 
current study, we showed that encapsulated DCC and TGF-β had similar effects on BMSC gene 
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expression in vitro, but encapsulated DCC had a greater effect on BMSC production of GAG and 
collagen than TGF-β. The encapsulation of DCC compromised the macro-structure of the matrix 
during solubilization and the DCC effect remained positive on the cells, this may indicate that 
the structure of the matrix is not vital to bioactivity induced by DCC. Additionally, the difference 
between the amounts of DCC material each scaffold type contained (coated vs. encapsulated) 
may have had an effect on the differences seen in cellular response. The response to DCC may 
be dose dependent. Additional work to identify an ideal loading dose may be beneficial for future 
work.  
 The decrease of encapsulated factors in PLGA microsphere-based scaffolds limits the 
duration of cellular response effects. The amount of DCC in both DCC-coated and DCC-
encapsulated groups was significantly decreased between day 0 and week 3. This trend matched 
the decrease in all gene expression at week 3 and subsequently the loss of biochemical content 
by week 6 in all cell seeded scaffolds. Although not specifically explored in the current study, 
previous studies have reported a burst release of encapsulated TGF-β resulting in a nearly 80% 
decrease of remaining TGF within the scaffolds at 3 weeks. The lack of sustained release of TGF 
would also contribute to the reduced chondrogenesis seen in TGF scaffolds by week 3.23 Using 
polymers with greater degradation times or fabricating microspheres to reduce the porosity on 
the surfaces may enhance extended release of encapsulated materials in vitro.  
Microsphere-based scaffolds are a promising alternative to current cartilage repair 
techniques due to the ability to control both their mechanical properties and to encapsulate a 
wide variety of materials.17, 18, 21, 23 Encapsulated materials can be selected to aid in stem cell 
differentiation and cartilage tissue repair.17 DCC was chosen for encapsulation and coating 
because of previous studies citing cartilage matrix as a potentially chondroinductive material.12, 
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14, 15, 30, 31 The use of decellularized cartilage instead of native or devitalized cartilage is 
advantageous from clinical and commercial standpoints because of decreased immunogenicity 
and long term storage of the material. Successful decellularization of tissues, i.e., complete 
removal of residual DNA and immunogenic antigens, may also eventually lead to safer 
xenogeneic tissue implants for all tissue types.10, 32, 33  
  In summary, DCC microsphere-based scaffolds led to gene expression and mechanical 
performance comparable to that of TGF-β, while outperforming both the TGF-β and control 
groups in biosynthesis, suggesting that DCC in a microsphere-based scaffold may indeed be 
bioactive, but additional work remains in terms of method of incorporation (i.e., coated vs. 
encapsulated) and dose to determine whether indeed a chondroinductive approach is achievable.  
In terms of the method of incorporation, the DCC-encapsulated group generally outperformed 
the DCC-coated group with the techniques presented.  Overall, using microsphere-based 
scaffolds as a means to incorporate and deliver DCC to regenerating cartilage may be a powerful 
tool in the future for treatment of cartilage defects. 
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CHAPTER 5: DISCUSSION 
 The overall goal of this thesis was to develop an ECM-based material for 
exploration and use in tissue engineered scaffolds for cartilage tissue engineering. Previous 
studies on the use of cartilage ECM for cartilage tissue engineering have reported numerous 
methods to obtain the matrix (tissue vs. in vitro derived) and process the matrix 
(decellularization vs. devitalization). Additionally, numerous methods have also been reported 
for manipulating the cartilage matrix material into a structurally functional scaffold. This thesis 
represents the first clear distinction between types of cartilage matrix and the processing 
methods. The studies reported in this thesis were the first to fully characterize cartilage matrix 
through both devitalization and decellularization processes. They were also the first report 
describing incorporation of DCC into microsphere-based scaffolds.  
 Cells cultured in pellets in the presence of DCC exhibited upregulation of chondrogenic 
gene markers including collagen II, Sox9 and aggrecan. Additionally, the cells cultured with 
DCC had greater amounts of DNA after 7 days than cells cultured with DVC. These findings 
indicated that the significant loss of GAG from the DCC material did not eliminate the effect the 
cartilage matrix had on the cells, although it is unknown if the loss of GAG content reduced the 
effect on cells or not. It is still unclear whether or not the differences seen between DCC and 
DVC in vitro would remain true in different culture conditions or in vivo with more homogenous 
nutrient access compared to cell pellets. The pellet culture results also showed that DCC had 
superior effects on cells compared to cells cultured in the presence of TGF-β. The simplicity, 
ease, and reduced need for biological manipulation when using DCC materials may contribute to 
the attraction and motivation for use of DCC with respect to FDA regulation and clinical 
delivery. This thesis only explored the changes in biochemical and DNA content through a 
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particular decellularization protocol. Additional work may be helpful in characterizing the 
potential immunogenicity of the material including determining if the alpha-Gal epitope (in 
xenogeneic materials) is removed during decellularization. Prior to delivery to a cartilage defect 
site, it may also be beneficial to determine if any other inflammatory responses due to the 
material exist in vivo.  
 DCC was successfully incorporated into microsphere-based scaffolds. The encapsulation 
of DCC in microspheres did not reduce mechanical performance of the scaffolds, however, the 
DCC surface coating process used did significantly reduce the mechanical properties of the 
scaffolds. If surface coating of microsphere scaffolds is explored in the future, a different 
technique that does not subject the scaffolds to acidic conditions may be favorable. However, 
when characterizing the cellular response to both encapsulated and coated scaffolds, coating 
scaffolds may not be necessary as DCC is released from microspheres quickly due to the high 
porosity of the surface. The cellular response seen in the microsphere scaffolds with DCC was 
limited by the amount of DCC remaining in the scaffolds. DCC-encapsulated scaffolds were able 
to incorporate greater amounts of DCC than the coated scaffolds. To improve the long-term 
release of materials from these scaffolds, a higher molecular weight polymer or greater loading 
concentration of DCC may be necessary.  
The mechanism by which DCC influences cellular response remains unclear. Even 
though DCC has superior effects compared to TGF-β in vitro, it does not imply that residual 
TGF-β (if any) within the matrix is responsible for the observed cellular response. Additionally, 
the pellet study used DCC with the microstructure still intact and the DCC-encapsulation 
sacrificed much of the microstructure of the tissue. The intact DCC used in the pellet study had a 
greater cellular response, which may suggest the microstructure of the DCC aided in enhanced 
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cellular response. The effect DCC had on cells seemed to have possibly been dose dependent in 
the microsphere scaffolds, however, dosage was not explored in the cell pellet characterization. 
Also, the cell pellets were in direct contact with the DCC and did not depend on the release of 
the material from a synthetic polymer, this direct exposure may have been beneficial for cell 
signaling. It must be noted that since the delivery mechanism of DCC to cells was different 
between the cell pellet and microsphere scaffolds comparison between the studies is limited.  
Future work should aim to understand the mechanism behind the bioactivity of DCC and effects 
of DCC dosage. The understanding of the mechanism may help aid in the design of even more 
simplistic acellular biomaterial approaches for cartilage regeneration.  
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APPENDIX A: Figures 
 
 
 
Figure 2.1: Cartilage matrix classifications. 
A schematic depicting the distinctions between cartilage matrix final products dependent 
on the source and processing.   
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Figure 3.1: Quantification of DNA loss during decellularization and devitalization. 
 
PicoGreen results depicting changes in double stranded (ds)DNA amounts in articular 
cartilage throughout the decellularization process. Processing the cartilage with both physical 
and chemical methods significantly reduced the amount of dsDNA in the matrix by 86%. * 
denotes p<0.01 (n=6). All results are reported as mean ± standard deviation.   
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Figure 3.2: GAG quantification during decellularization and devitalization. 
 
DMMB assay results depicting change in glycosaminoglycan (GAG) content of cartilage 
matrix during physical and chemical decellularization. Only DCC (both physical and chemical 
methods) significantly reduced the GAG content in the cartilage matrix by 55%. * denotes 
p<0.01 (n=6) All results are reported as mean ± standard deviation.  
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Figure 3.3: Hydroxyproline quantification during decellularization and devitalization. 
 
Hydroxyproline content of cartilage matrix during physical and chemical 
decellularization process. No statically significant differences were observed during the 
processing (n=6). All results are reported as mean ± standard deviation.  
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Figure 3.4: DNA quantification of cell pellets. 
 
DNA content of cell pellets at days 1 and 7 (n=5). All groups significantly increased 
DNA content between 1 and 7 days. * p<0.05 between day 1 and 7, ** p<0.01 between day 1 
and 7, A = p<0.05 between DCC and control, and B = p<0.01 between DCC and DVC. All 
results are reported as mean ± standard deviation.  
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Figure 3.5: SEM images of DCC. 
 
SEM images of DCC following size exclusion sieving. (A) Cryo-ground DCC prior to 
separation, scale bar 1 mm (B) 350 µm, scale bar 200 µm (C) 100 µm, scale bar 100 µm (D) 45 
µm meshes, scale bar 100 µm. 
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Figure 3.6: qPCR results. 
 
Relative expression of chondrogenic and osteogenic gene markers (n=5). A) collagen II, B) 
Sox-9, C) aggrecan, D) collagen X, E) Runx-2, and F) collagen I. @ denotes significant 
difference from control group at same time point, # denotes significant difference from TGF-β 
group at same time point, * denotes significant difference between day 1 value, + denotes 
significant difference from previous time point, $ denotes significant difference from DCC group 
at same time point.  
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Figure 4.1: Microsphere morphology. 
SEM images of microsphere morphology. Both TGF and DCC-encapsulated microspheres have 
porous surfaces compared to PLGA microspheres that have a smooth surface. A) PLGA 
microsphere, B) DCC-encapsulated microsphere, and C) TGF microsphere. 
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Figure 4.2: SEM and EDS of DCC-encapsulated microspheres. 
A) SEM image of DCC-encapsulated microsphere B) EDS pixel map depicting location of 
nitrogen on the surface of the DCC-encapsulated microsphere. Scale bars are 10 µm.   
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Figure 4.3: Hydroxyproline and GAG content. 
Remaining GAG and hydroxyproline in DCC-encapsulated and DCC-coated scaffolds at day 0, 
week 3 and week 6. All scaffolds exhibited a decrease in biochemical content by week 3 
(p<0.05). 
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Figure 4.4: Relative loss of hydroxyproline and GAG content. 
 
Relative loss of A) hydroxyproline and B) GAG from DCC-Coated and DCC-
Encapsulated scaffolds. By week 6 a greater proportion of hydroxyproline was lost from the 
DCC-Coated scaffolds and an equal proportion of GAG was lost from each type of scaffold. 
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Figure 4.5: DNA content of all cell seeded scaffolds. 
 
PicoGreen results depicting greater DNA content on DCC-coated scaffolds at day 0. * 
denotes statistically significant difference from all other groups at same time and subsequent 
times of same group (p<0.05). Data is reported as mean ± standard deviation.    
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Figure 4.6: Biochemical content of all cell seeded scaffolds. 
 
Biochemical content of engineered constructs (n=5). Note that HYP and GAG contents 
were measured for acellular scaffolds containing DCC and subtracted out as a baseline value. A) 
Hydroxyproline content on all scaffolds, a decrease in hydroxyproline is observed following 
week 3 on all scaffolds. B) GAG content on all scaffolds, also with a decrease in content 
following week 3.* denotes statistically significant difference from day 0 value, @ denotes 
statistically significant difference from blank group at same time point, $ denotes statistically 
significant difference from TGF group at same time point, and + denotes statistically significant 
difference from DCC at same time point. All significance reported for (p<0.05). Data is reported 
as mean ± standard deviation.   
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Figure 4.7: Compressive elastic moduli of all acellular scaffolds. 
 
The compressive elastic moduli of engineered scaffolds prior to cell seeding (n=4-5). The 
DCC-coated scaffolds had significantly lower compressive moduli than the blank, TGF, and 
DCC-encapsulated scaffolds. *denotes significance from blank scaffolds (p<0.05) and $ denotes 
significance from DCC-coated scaffolds. Data is reported as mean ± standard deviation.  
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Figure 4.8: RT-qPCR results. 
 
RT-qPCR results for all scaffolds and time points (n=5). A) Collagen II expression was 
significantly greater in TGF scaffolds compared to all others. B) Sox9 expression was 
significantly lower in DCC-coated scaffolds at day 0 compared to all other scaffolds. C) 
Aggrecan expression was nearly equal among all scaffold types during culture. D) Collagen I 
expression was lower in both TGF and DCC-encapsulated scaffolds at day 0. E) Runx2 
expression was greatest in blank scaffolds at day 0. * denotes significant from time 0 value 
(same group), @ denotes significant from blank at same time point, $ denotes significant from 
TGF at same time point, & denotes significant from DCC-coated at same time point. For all 
significance noted (p<0.05). Data is reported as mean ± standard deviation. 
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Figure 4.9: Immunohistochemistry images. 
 
IHC staining of DCC-encapsulated scaffolds at week 3. Staining was positive for 
collagen II, collagen I, and aggrecan. Collagen I staining was more intense in the cell-seeded 
group compared to the acellular group. 
 
 
  
 
 
88 
  
 
APPENDIX B: Tables 
 
Table 2.1: Common decellularization reagents. 
 
A general list of common chemicals used in decellularizing cartilage with the chemical 
description and the purpose of the chemical for decellularization. 
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Table 2.2: Key in vivo studies. 
 
A summary of key in vivo studies that have delivered cartilage matrix derived scaffolds to 
cartilage defect sites. Defect sites are all in the femoral condyle unless otherwise noted. 
Abbreviations: DCC = Decellularized native cartilage (Fig. 2.1), BMSC = bone-marrow derived 
mesenchymal stem cell, ASC = adipose derived stem cell, MSC = mesenchymal stem cell 
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Table 2.3: Summary of patents describing cartilage matrix materials. 
 
Summary of current patent applications and awarded patents describing formulations of 
cartilage matrices as of May 25, 2014. Abbreviations: DVC = devitalized native cartilage, DCC 
= decellularized native cartilage, DCCM = decellularized cell derived matrix, DVCM = 
devitalized cell derived matrix, CDM = cell derived matrix (Fig. 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
